Breast Cancer: Molecular Pathogenesis and Targeted Therapy

Abstract

Breast cancer (BC) is the most prevalent cancer in women and remains the leading cause of cancer-related mortality globally. Its development is influenced by multiple factors, including genetics, environmental, aging, and modulation of various signaling pathways. The heterogeneity of BC together with the emergence of treatment resistance and recurrence have prompted researchers to explore and develop new therapeutic approaches. Recently, oncology research has primarily focused on the development of targeted therapies against molecular abnormalities in BC. These therapies include monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates, PI3K/Akt/mTOR pathway inhibitors, CDK 4/6 inhibitors, PARP inhibitors, antiangiogenic agents, and various other targeted drugs. Immunomodulatory strategies, including immune checkpoint inhibitors (anti-PD-1/PD-L1), CTLA-4 blockers, adoptive T-cell therapy, and cancer vaccines, stimulate immune response against cancer cells. Epigenetic therapies like DNMT and HDAC inhibitors have also shown promise in BC treatment. This review highlights how innovative approaches like targeting intratumoral heterogeneity, liquid biopsy for resistance mutation detection, bypass mechanisms (FGFR1 activation following CDK4/6 inhibition), artificial intelligence-based drug discovery, patient-derived organoids, and adaptive trial designs are shaping BC treatment. By combining molecular insights with precision therapeutics, these advancements offer significant potential to address resistance, improve efficacy, and enhance patient outcomes.

Keywords

artificial intelligence / breast cancer subtypes / PI3K/Akt/mTOR inhibitors / PARP inhibitors / targeted therapy / tumor microenvironment

References

[1] E. I. Obeagu and G. U. Obeagu, “Breast Cancer: A Review of Risk Factors and Diagnosis,” Medicine (United States) 103, no. 3 (2024): E36905.

[2] B. Smolarz, A. Zadrożna Nowak, and H. Romanowicz, “Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature),” Cancers 14, no. 10 (2022): 2569.

[3] A. N. Giaquinto, H. Sung, L. A. Newman, et al., “Breast Cancer Statistics 2024,” CA: A Cancer Journal for Clinicians 74, no. 6 (2024): 477-495.

[4] S. Wu, Y. Zheng, and O. I. Olopade, “The Convergence of Genomic Medicine and Translational Omics in Transforming Breast Cancer Patient Care,” Journal of Clinical Investigation 134, no. 21 (2024): e187520.

[5] J. Kim, A. Harper, V. McCormack, et al., “Global Patterns and Trends in Breast Cancer Incidence and Mortality Across 185 Countries,” Nature Medicine 31, no. 4 (2025): 1154-1162. Published online February 24, 2025:1-9.

[6] H. Xu and B. Xu, “Breast Cancer: Epidemiology, Risk Factors and Screening,” Chinese Journal of Cancer Research 35, no. 6 (2023): 565.

[7] C. C. Twort and A. C. Bottomley, “The Etiology of Breast Cancer,” Lancet 220, no. 5693 (2022): 776-780.

[8] L. Lopez-Gonzalez, A. Sanchez Cendra, C. Sanchez Cendra, et al., “Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice,” Medicina (Kaunas) 60, no. 1 (2024): 168.

[9] C. J. Li, Y. D. T. Tzeng, Y. H. Chiu, H. Y. Lin, M. F. Hou, and P. Y. Chu, “Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer,” Cancers 13, no. 12 (2021): 2978.

[10] Y. Chhichholiya, P. Suman, S. Singh, and A. Munshi, “The Genomic Architecture of Metastasis in Breast Cancer: Focus on Mechanistic Aspects, Signalling Pathways and Therapeutic Strategies,” Medical Oncology 38, no. 8 (2021): 1-23.

[11] X. D. Mao, X. Wei, T. Xu, T. P. Li, and K. S. Liu, “Research Progress in Breast Cancer Stem Cells: Characterization and Future Perspectives,” American Journal of Cancer Research 12, no. 7 (2022): 3208, Accessed March 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9360222/.

[12] H. Yousefi, A. Bahramy, N. Zafari, et al., “Notch Signaling Pathway: A Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer,” BMC Cancer 22, no. 1 (2022): 1-21.

[13] I. Rasool, A. H. Bhat, N. Khurshid, I. Andrabi, Q. Qadir, and S. A. Ganie, “Navigating Breast Cancer Complexity: Deciphering the Cross Talk of Wnt/β Catenin and Notch Pathways in Development and Diseases,” Authorea Preprints, https://doi.org/10.22541/AU.171619034.42959230/V1.

[14] V. K. Panda, B. Mishra, S. Mahapatra, et al., “Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review,” Cancers 17, no. 2 (2025): 234.

[15] L. Guo, D. Kong, J. Liu, et al., “Breast Cancer Heterogeneity and Its Implication in Personalized Precision Therapy,” Experimental Hematology & Oncology 12, no. 1 (2023): 1-27.

[16] M. A. Samad, I. Ahmad, T. A. Zughaibi, et al., “Nanotechnology-Based Drug Delivery for Breast Cancer Treatment: Current Applications and Future Directions,” European Journal Of Medicinal Chemistry Reports 14 (2025): 100268.

[17] H. Y. Min and H. Y. Lee, “Molecular Targeted Therapy for Anticancer Treatment,” Experimental & Molecular Medicine 54, no. 10 (2022): 1670-1694.

[18] A. Mukherjee and D. Bandyopadhyay, “Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs,” Cancers 16, no. 20 (2024): 3517.

[19] H. Jin, L. Wang, and R. Bernards, “Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges,” Nature Reviews Drug Discovery 22, no. 3 (2022): 213-234.

[20] R. Kaur, A. Bhardwaj, and S. Gupta, “Cancer Treatment Therapies: Traditional to Modern Approaches to Combat Cancers,” Molecular Biology Reports 50, no. 11 (2023): 9663-9676.

[21] Z. D. Shi, K. Pang, Z. X. Wu, et al., “Tumor Cell Plasticity in Targeted Therapy-Induced Resistance: Mechanisms and New Strategies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 1-21.

[22] M. Labrie, J. S. Brugge, G. B. Mills, and I. K. Zervantonakis, “Therapy Resistance: Opportunities Created by Adaptive Responses to Targeted Therapies in Cancer,” Nature Reviews Cancer 22, no. 6 (2022): 323-339.

[23] X. Sun, K. Liu, S. Lu, W. He, and Z. Du, “Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer,” Cancers 14, no. 21 (2022): 5456.

[24] L. Kumari, L. Mishra, P. Patel, N. Sharma, G. D. Gupta, and B. D. Kurmi, “Emerging Targeted Therapeutic Strategies for the Treatment of Triple-Negative Breast Cancer,” Journal of Drug Targeting 31, no. 9 (2023): 889-907.

[25] K. H. Lau, A. M. Tan, Y. Shi, K. H. Lau, A. M. Tan, and Y. Shi, “New and Emerging Targeted Therapies for Advanced Breast Cancer,” International Journal of Molecular Sciences 23, no. 4 (2022): 2288.

[26] H. Zhong, Z. Zhou, and H. Wang, “The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review,” International Journal of Molecular Sciences 25, no. 24 (2024): 13376.

[27] A. Nicolini and P. Ferrari, “Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way Beyond,” Cancers 16, no. 2 (2024): 466.

[28] M. J. Bou-Dargham, S. Draughon, V. Cantrell, Z. I. Khamis, and Q. X. A. Sang, “Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy,” Journal of Cancer 12, no. 23 (2021): 6949.

[29] H. Shewale and A. Kanugo, “Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer,” Current Pharmaceutical Biotechnology 25, no. 3 (2024): 365-391.

[30] M. Saint-Ghislain, C. Levenbruck, and A. Bellesoeur, “Adverse Events of Targeted Therapies Approved for Women's Cancers,” International Journal of Women's Dermatology 7, no. 5 (2021): 552-559.

[31] F. Ye, S. Dewanjee, Y. Li, et al., “Advancements in Clinical Aspects of Targeted Therapy and Immunotherapy in Breast Cancer,” Molecular Cancer 22, no. 1 (2023): 1-40.

[32] S. Łukasiewicz, M. Czeczelewski, A. Forma, J. Baj, R. Sitarz, and A. Stanisławek, “Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review,” Cancers 13, no. 17 (2021): 4287.

[33] G. M. A. Ajabnoor, “The Molecular and Genetic Interactions Between Obesity and Breast Cancer Risk,” Medicina (Kaunas). 59, no. 7 (2023): 1338.

[34] X. Xiong, L. W. Zheng, Y. Ding, et al., “Breast Cancer: Pathogenesis and Treatments,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 1-33.

[35] L. Wang, S. Zhang, and X. Wang, “The Metabolic Mechanisms of Breast Cancer Metastasis,” Frontiers in Oncology 10 (2021): 602416.

[36] J. Wang, P. Singh, K. Yin, et al., “Disease Spectrum of Breast Cancer Susceptibility Genes,” Frontiers in Oncology 11 (2021): 663419.

[37] S. Y. Ouedraogo, A. A. Zoure, M. M. J. Zeye, et al., “BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 Genes Mutations in Burkina Faso Breast Cancer Patients: Prevalence, Spectrum and Novel Variant,” Molecular Genetics and Genomics 297, no. 5 (2022): 1257-1268.

[38] M. Roy, J. Biswas, and A. Datta, “Genetics and Epigenetics of Breast Cancer,” Genet Epigenetics Breast Cancer 1-87, https://doi.org/10.1007/978-981-19-9925-3/COVER.

[39] L. Nicosia, L. Mariano, G. Pellegrino, et al., “Atypical Ductal Hyperplasia and Lobular in Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention,” Cancers (Basel) 16, no. 4 (2024): 837.

[40] J. Timbres, K. Kohut, M. Caneppele, et al., “DCIS and LCIS: Are the Risk Factors for Developing in Situ Breast Cancer Different?,” Cancers (Basel) 15, no. 17 (2023): 4397.

[41] R. Liu, Y. Yu, Q. Wang, et al., “Interactions Between Hedgehog Signaling Pathway and the Complex Tumor Microenvironment in Breast Cancer: Current Knowledge and Therapeutic Promises,” Cell Communication and Signaling 22, no. 1 (2024): 1-17.

[42] P. Garg, S. Ramisetty, M. Nair, et al., “Strategic Advancements in Targeting the PI3K/AKT/mTOR Pathway for Breast Cancer Therapy,” Biochemical Pharmacology 236 (2025): 116850.

[43] M. A. Samad, I. Ahmad, M. N. Asghar, et al., “MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics,” Seminars in Oncology 52, no. 5 (2025): 152386.

[44] K. Dvir, S. Giordano, and J. P. Leone, “Immunotherapy in Breast Cancer,” International Journal of Molecular Sciences 25, no. 14 (2024): 7517.

[45] E. Orrantia-Borunda, P. Anchondo-Nuñez, L. E. Acuña-Aguilar, F. O. Gómez-Valles, and C. A. Ramírez-Valdespino, “Subtypes of Breast Cancer,” Breast Cancer (Tokyo, Japan) 31-42, https://doi.org/10.36255/EXON-PUBLICATIONS-BREAST-CANCER-SUBTYPES.

[46] M. Kaleem, M. Thool, N. G. Dumore, et al., “Management of Triple-Negative Breast Cancer by Natural Compounds Through Different Mechanistic Pathways,” Frontiers in Genetics 15 (2024): 1440430.

[47] S. Labidi, N. Mulla, I. E. Elkholi, et al., “High Ki-67 Expression Is Associated With Increased Risk of Distant Recurrence in Oncotype Dx Low Risk Breast Cancer,” Clinical Breast Cancer 25, no. 6 (2025): e690-e696. e1.

[48] L. Clusan, F. Ferrière, G. Flouriot, and F. Pakdel, “A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer,” International Journal of Molecular Sciences 24, no. 7 (2023): 6834.

[49] N. Afifi and C. A. Barrero, “Understanding Breast Cancer Aggressiveness and Its Implications in Diagnosis and Treatment,” Journal of Clinical Medicine 12, no. 4 (2023): 1375.

[50] B. Kang, J. Lee, J. H. Jung, W. W. Kim, H. Keum, and H. Y. Park, “Differences in Clinical Outcomes Between HER2-Negative and HER2-Positive Luminal B Breast Cancer,” Med (United States) 102, no. 34 (2023): E34772.

[51] E. Carvalho, S. Canberk, F. Schmitt, and N. Vale, “Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies,” Cancers (Basel) 17, no. 7 (2025): 1102.

[52] F. Andre, T. Filleron, M. Kamal, et al., “Genomics to Select Treatment for Patients With Metastatic Breast Cancer,” Nature 610, no. 7931 (2022): 343-348.

[53] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46.

[54] M. A. Harris, P. Savas, B. Virassamy, et al., “Towards Targeting the Breast Cancer Immune Microenvironment,” Nature Reviews Cancer 24, no. 8 (2024): 554-577.

[55] K. Umadevi, L. G. Priyanka, R. Clementina, E. S. Rao, D. Sundeep, and S. Kumari, “An Update and Translational Perspective in Genetics and Genomics of Breast Cancer,” Current Breast Cancer Reports 17, no. 1 (2025): 1-15.

[56] A. F. Garibaldi-Ríos, L. E. Figuera, G. M. Zúñiga-González, et al., “Genomic Landscape of Breast Cancer: Study across Diverse Ethnic Groups,” Diseases 13, no. 3 (2025): 86.

[57] P. Selenica, H. Dopeso, M. Repetto, et al., “Genomic Landscape of Breast Cancer in Elderly Patients,” Npj Breast Cancer 11, no. 1 (2025): 1-10.

[58] M. Galogre, D. Rodin, M. Pyatnitskiy, M. Mackelprang, and I. Koman, “A Review of HER2 Overexpression and Somatic Mutations in Cancers,” Critical Reviews in Oncology/Hematology 186 (2023): 103997.

[59] X. Cheng, “A Comprehensive Review of HER2 in Cancer Biology and Therapeutics,” Genes 15, no. 7 (2024): 903.

[60] G. Bon, F. S. Di Lisa, L. Filomeno, et al., “HER2 mutation as an Emerging Target in Advanced Breast Cancer,” Cancer Science 115, no. 7 (2024): 2147-2158.

[61] L. Pan, J. Li, Q. Xu, et al., “HER2/PI3K/AKT Pathway in HER2-Positive Breast Cancer a Review,” Medicine (United States) 103, no. 24 (2024): e38508.

[62] S. Asgari-Karchekani, A. Aryannejad, S. A. Mousavi, S. Shahsavarhaghighi, and S. M. Tavangar, “The Role of HER2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and HER2-Targeted Therapies: A Comprehensive Review,” Medical Oncology 39, no. 12 (2022): 1-15.

[63] M. Fillbrunn, J. Signorovitch, F. André, et al., “PIK3CA mutation Status, Progression and Survival in Advanced HR + /HER2- Breast Cancer: A Meta-Analysis of Published Clinical Trials,” BMC Cancer 22, no. 1 (2022): 1-11.

[64] S. Giannoni-Luza, O. Acosta, A. G. Murillo Carrasco, et al., “Chip-Based Digital Polymerase Chain Reaction as Quantitative Technique for the Detection of PIK3CA Mutations in Breast Cancer Patients,” Heliyon 8, no. 11 (2022): e11396.

[65] K. Reinhardt, K. Stückrath, C. Hartung, et al., “PIK3CA-Mutations in Breast Cancer,” Breast Cancer Research and Treatment 196, no. 3 (2022): 483-493.

[66] Q. Huang, Y. Zhou, B. Wang, Y. Zhao, F. Zhang, and B. Ding, “Mutational Landscape of Pan-Cancer Patients With PIK3CA Alterations in Chinese Population,” BMC Medical Genomics 15, no. 1 (2022): 1-12.

[67] A. R. Rasti, A. Guimaraes-Young, F. Datko, V. F. Borges, D. L. Aisner, and E. Shagisultanova, “PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer,” JCO Precision Oncology 6 (2022): e2100370.

[68] Y. B. Cho and K. S. Park, “The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions,” Medicine 61, no. 3 (2025): 518.

[69] A. Calabrese, C. von Arx, A. A. Tafuti, M. Pensabene, and M. De Laurentiis, “Prevention, Diagnosis and Clinical Management of Hereditary Breast Cancer Beyond BRCA1/2 Genes,” Cancer Treatment Reviews 129 (2024): 102785.

[70] P. X. Lim, M. Zaman, W. Feng, and M. Jasin, “BRCA2 promotes Genomic Integrity and Therapy Resistance Primarily Through Its Role in Homology-Directed Repair,” Molecular Cell 84, no. 3 (2024): 447-462. e10.

[71] C. Shao, M. S. Chang, F. C. Lam, et al., “A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer,” Journal of Oncology 2022, no. 1 (2022): 5830475.

[72] B. Arun, F. J. Couch, J. Abraham, N. Tung, and P. A. Fasching, “BRCA-Mutated Breast Cancer: The Unmet Need, Challenges and Therapeutic Benefits of Genetic Testing,” British Journal of Cancer 131, no. 9 (2024): 1400-1414.

[73] S. Yadav, N. J. Boddicker, J. Na, et al., “Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2,” Journal of Clinical Oncology 41, no. 9 (2023): 1703-1713.

[74] E. Kang, J. J. Jung, C. Lim, et al., “Increased Risk of Contralateral Breast Cancer for BRCA1/2 Wild-Type, High-Risk Korean Breast Cancer Patients: A Retrospective Cohort Study,” Breast Cancer Research 26, no. 1 (2024): 1-9.

[75] P. Pourmasoumi, A. Moradi, and M. Bayat, “BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review,” Reproductive Sciences 31, no. 12 (2024): 3624-3634.

[76] A. Toss, O. Ponzoni, B. Riccò, et al., “Management of PALB2-Associated Breast Cancer: A Literature Review and Case Report,” Clinical Case Reports 11, no. 8 (2023): e7747.

[77] T. K. Foo and B. Xia, “BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer,” Cancer Research 82, no. 18 (2022): 3191-3197.

[78] M. A. Kausar, K. F. Alshammari, F. Alenazi, et al., “RAD51 and PALB2 in Precision Oncology: Clinical Implications for HRD Associated Breast and Ovarian Cancers (Review),” International Journal of Oncology 67, no. 2 (2025): 65.

[79] T. L. M. Ruberu, D. Braun, G. Parmigiani, and S. Biswas, “Meta-Analysis of Breast Cancer Risk for Individuals With PALB2 Pathogenic Variants,” Genetic Epidemiology 48, no. 8 (2024): 448-454.

[80] J. Li, P. He, Q. Cai, et al., “Spectrum and Characteristics of Germline PALB2 Pathogenic Variants in 1556 Early-Onset Breast Cancer Patients in China,” Journal of Cancer Research and Clinical Oncology 150, no. 6 (2024): 1-9.

[81] M. M. Tsyganov, S. S. Sorokovikova, E. A. Lutzkaya, and M. K. Ibragimova, “Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship With the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis,” Genes (Basel) 14, no. 8 (2023): 1554.

[82] A. Kwong, V. Y. Shin, C. Y. S. Ho, et al., “Germline palb2 Mutation in High-Risk chinese Breast and/or Ovarian Cancer Patients,” Cancers (Basel) 13, no. 16 (2021): 4195.

[83] S. Xia and Q. Lin, “Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer,” Technology in Cancer Research & Treatment 21 (2022): 15330338221090351.

[84] S. K. Herzog and S. A. W. Fuqua, “ESR1 mutations and Therapeutic Resistance in Metastatic Breast Cancer: Progress and Remaining Challenges,” British Journal of Cancer 126, no. 2 (2021): 174-186.

[85] Z. Li, Y. Wu, M. E. Yates, et al., “Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis,” Cancer Research 82, no. 7 (2022): 1321-1339.

[86] Z. Nagy and R. Jeselsohn, “ESR1 fusions and Therapeutic Resistance in Metastatic Breast Cancer,” Frontiers in Oncology 12 (2023): 1037531.

[87] J. O. Brett, L. M. Spring, A. Bardia, and S. A. Wander, “ESR1 mutation as an Emerging Clinical Biomarker in Metastatic Hormone Receptor-Positive Breast Cancer,” Breast Cancer Research 23, no. 1 (2021): 1-15.

[88] L. Gerratana, A. A. Davis, M. Velimirovic, et al., “Interplay Between ESR1/PIK3CA Codon Variants, Oncogenic Pathway Alterations and Clinical Phenotype in Patients With Metastatic Breast Cancer (MBC): Comprehensive Circulating Tumor DNA (ctDNA) Analysis,” Breast Cancer Research 25, no. 1 (2023): 1-12.

[89] S. Putti, A. Giovinazzo, M. Merolle, M. L. Falchetti, and M. Pellegrini, “ATM Kinase Dead: From Ataxia Telangiectasia Syndrome to Cancer,” Cancers 13, no. 21 (2021): 5498.

[90] S. Ueno, T. Sudo, and A. Hirasawa, “ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors,” International Journal of Molecular Sciences 23, no. 1 (2022): 523.

[91] H. Zhao, J. Li, Z. You, H. D. Lindsay, and S. Yan, “Distinct Regulation of ATM Signaling by DNA Single-Strand Breaks and APE1,” Nature Communications 15, no. 1 (2024): 1-17.

[92] L. M. Phan and A. H. Rezaeian, “ATM: Main Features, Signaling Pathways, and Its Diverse Roles in DNA Damage Response, Tumor Suppression, and Cancer Development,” Genes 12, no. 6 (2021): 845.

[93] L. S. Stucci, V. Internò, M. Tucci, et al., “The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice,” Genes 12, no. 5 (2021): 727.

[94] M. Moslemi, Y. Moradi, H. Dehghanbanadaki, et al., “The Association Between ATM Variants and Risk of Breast Cancer: A Systematic Review and Meta-Analysis,” BMC Cancer 21, no. 1 (2021): 1-12.

[95] A. L. Renault, J. G. Dowty, J. A. Steen, et al., “Population-Based Estimates of Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in ATM,” Breast Cancer Research 24, no. 1 (2022): 1-6.

[96] C. Marvalim, A. Datta, and S. C. Lee, “Role of p53 in Breast Cancer Progression: An Insight Into p53 Targeted Therapy,” Theranostics 13, no. 4 (2023): 1421.

[97] E. Blondeaux, L. Arecco, K. Punie, et al., “Germline TP53 Pathogenic Variants and Breast Cancer: A Narrative Review,” Cancer Treatment Reviews 114 (2023): 102522.

[98] Z. Li, N. S. Spoelstra, M. J. Sikora, et al., “Mutual Exclusivity of ESR1 and TP53 Mutations in Endocrine Resistant Metastatic Breast Cancer,” Npj Breast Cancer 8, no. 1 (2022): 1-13.

[99] A. Horvat, A. Tadijan, I. Vlašić, and N. Slade, “p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies,” Cancers 13, no. 12 (2021): 2885.

[100] X. Wang, J. Yang, W. Yang, et al., “Multiple Roles of p53 in Cancer Development: Regulation of Tumor Microenvironment, m6A Modification and Diverse Cell Death Mechanisms,” Journal of Advanced Research 75 (2025): 539-560, https://doi.org/10.1016/J.JARE.2024.10.026. Published online October 28, 2024.

[101] X. Huang, D. Zhang, D. Zhang, et al., “Decoding PTEN: From Biological Functions to Signaling Pathways in Tumors,” Molecular Biology Reports 51, no. 1 (2024): 1-12.

[102] L. Derkyi-Kwarteng, F. N. Ghartey, E. Aidoo, et al., “A Retrospective Analysis Suggests PTEN Expression Is Associated With Favorable Clinicopathological Features of Breast Cancer,” Scientific Reports 14, no. 1 (2024): 1-7.

[103] J. Chen, J. Sun, Q. Wang, et al., “Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis,” Frontiers in Oncology 12 (2022): 825484.

[104] A. Glaviano, A. S. C. Foo, H. Y. Lam, et al., “PI3K/AKT/mTOR Signaling Transduction Pathway and Targeted Therapies in Cancer,” Molecular Cancer 22, no. 1 (2023): 1-37.

[105] K. Yari, A. Hakimi, M. Mohammadi, M. Ammari-Allahyari, N. Salari, and H. Ghasemi, “The Association of PTEN Gene Mutations With the Breast Cancer Risk: A Systematic Review and Meta-Analysis,” Biochemical Genetics 62, no. 3 (2024): 1617-1635.

[106] B. Sicairos, S. Alam, and Y. Du, “A Comprehensive Analysis of Different Types of Databases Reveals That CDH1 mRNA and E-Cadherin Protein Are Not Downregulated in Most Carcinoma Tissues and Carcinoma Cell Lines,” BMC Cancer 23, no. 1 (2023): 1-18.

[107] H. Dopeso, A. M. Gazzo, F. Derakhshan, et al., “Genomic and Epigenomic Basis of Breast Invasive Lobular Carcinomas Lacking CDH1 Genetic Alterations,” npj Precision Oncology 8, no. 1 (2024): 1-11.

[108] A. Sengupta and R. Banerjee, “An Investigation towards Understanding the Role of CDH1 Gene in Different Types of Breast Cancers,” BioRxiv, https://doi.org/10.1101/2021.01.11.426236.

[109] L. A. Gamble, P. H. McClelland, M. E. Teke, et al., “Defining Features of Hereditary Lobular Breast Cancer due to CDH1 With Magnetic Resonance Imaging and Tumor Characteristics,” Npj Breast Cancer 9, no. 1 (2023): 1-10.

[110] S. R. Taha and F. Boulos, “E-Cadherin Staining in the Diagnosis of Lobular versus Ductal Neoplasms of the Breast: The Emperor Has no Clothes,” Histopathology 86, no. 3 (2025): 327-340.

[111] G. Corso, E. Marino, C. Zanzottera, et al., “CDH1 Genotype Exploration in Women with Hereditary Lobular Breast Cancer Phenotype,” JAMA Network Open 7, no. 4 (2024): e247862-e247862.

[112] E. Adib, T. El Zarif, A. H. Nassar, et al., “CDH1 germline Variants Are Enriched in Patients With Colorectal Cancer, Gastric Cancer, and Breast Cancer,” British Journal of Cancer 126, no. 5 (2022): 797-803.

[113] M. Pal, D. Das, and M. Pandey, “Understanding Genetic Variations Associated With Familial Breast Cancer,” World Journal of Surgical Oncology 22, no. 1 (2024): 1-15.

[114] C. E. McCarthy-Leo, G. S. Brush, R. Pique-Regi, F. Luca, M. A. Tainsky, and R. L. Finley, “Comprehensive Analysis of the Functional Impact of Single Nucleotide Variants of human CHEK2,” Plos Genetics 20, no. 8 (2024): e1011375.

[115] M. T. M. van Jaarsveld, D. Deng, D. Ordoñez-Rueda, M. Paulsen, E. A. C. Wiemer, and Z. Zi, “Cell-Type-Specific Role of CHK2 in Mediating DNA Damage-Induced G2 Cell Cycle Arrest,” Oncogenesis 9, no. 3 (2020): 1-7.

[116] D. M. Conde, “CHEK2 variants, Breast Cancer, and Implications for Management: A Narrative Review,” Translational Research in Breast Cancer 0, no. 0 (2023), https://doi.org/10.21037/tbcr-2.

[117] L. N. Weis, B. L. Bychkovsky, A. R. Hernandez, R. Barroso-Sousa, and R. L. Sandoval, “CHEK2-Related Breast Cancer: Real-World Challenges,” Familial Cancer 24, no. 1 (2025): 1-8.

[118] S. L. Carey-Smith, R. S. Kotecha, L. C. Cheung, and S. Malinge, “Insights Into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer,” International Journal of Molecular Sciences 25, no. 13 (2024): 6815.

[119] E. Besedina and F. Supek, “Copy Number Losses of Oncogenes and Gains of Tumor Suppressor Genes Generate Common Driver Mutations,” Nature Communications 15, no. 1 (2024): 1-20.

[120] P. Shahrouzi, F. Forouz, A. Mathelier, V. N. Kristensen, and P. H. G. Duijf, “Copy Number Alterations: A Catastrophic Orchestration of the Breast Cancer Genome,” Trends in Molecular Medicine 30, no. 8 (2024): 750-764.

[121] V. Gupta, V. Vashisht, A. Vashisht, et al., “Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors,” Genes (Basel) 15, no. 4 (2024): 396.

[122] M. P. Nguyen, W. C. Chen, K. Mirchia, et al., “Pan-cancer Copy Number Analysis Identifies Optimized Size Thresholds and co-occurrence Models for Individualized Risk Stratification,” Nature Communications 16, no. 1 (2025): 1-14.

[123] F. Bozzi, E. Conca, M. Silvestri, et al., “Detecting Gene Copy Number Alterations by Oncomine Comprehensive Genomic Profiling in a Comparative Study on FFPE Tumor Samples,” Scientific Reports 15, no. 1 (2025): 1-11.

[124] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374-403.

[125] Y. Zhao, M. Shen, L. Wu, et al., “Stromal Cells in the Tumor Microenvironment: Accomplices of Tumor Progression?,” Cell Death & Disease 14, no. 9 (2023): 1-24.

[126] O. Habanjar, R. Bingula, C. Decombat, M. Diab-Assaf, F. Caldefie-Chezet, and L. Delort, “Crosstalk of Inflammatory Cytokines Within the Breast Tumor Microenvironment,” International Journal of Molecular Sciences 24, no. 4 (2023): 4002.

[127] J. Fang, Y. Lu, J. Zheng, et al., “Exploring the Crosstalk Between Endothelial Cells, Immune Cells, and Immune Checkpoints in the Tumor Microenvironment: New Insights and Therapeutic Implications,” Cell Death & Disease 14, no. 9 (2023): 1-15.

[128] M. Sadeghi, S. Dehnavi, M. Sharifat, A. M. Amiri, and A. Khodadadi, “Innate Immune Cells: Key Players of Orchestra in Modulating Tumor Microenvironment (TME),” Heliyon 10, no. 5 (2024): e27480.

[129] S. Pernot, S. Evrard, and A. M. Khatib, “The Give-and-Take Interaction between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression,” Frontiers in Immunology 13 (2022): 850856.

[130] Q. Wang, X. Shao, Y. Zhang, et al., “Role of Tumor Microenvironment in Cancer Progression and Therapeutic Strategy,” Cancer Medicine 12, no. 10 (2023): 11149-11165.

[131] T. Gerashchenko, A. Frolova, M. Patysheva, et al., “Breast Cancer Immune Landscape: Interplay between Systemic and Local Immunity,” Advanced Biology 8, no. 7 (2024): 2400140.

[132] G. Angelico, G. Broggi, G. Tinnirello, et al., “Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications From Pathologist's Perspective,” Cancers 15, no. 18 (2023): 4479.

[133] G. Gunaydin, “CAFs Interacting with TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion,” Frontiers in Oncology 11 (2021): 668349.

[134] S. He, L. Zheng, and C. Qi, “Myeloid-derived Suppressor Cells (MDSCs) in the Tumor Microenvironment and Their Targeting in Cancer Therapy,” Molecular Cancer 24, no. 1 (2025): 1-24.

[135] X. Han, X. Song, Z. Xiao, et al., “Study on the Mechanism of MDSC-platelets and Their Role in the Breast Cancer Microenvironment,” Frontiers in Cell and Developmental Biology 12 (2024): 1310442.

[136] S. Niland, A. X. Riscanevo, and J. A. Eble, “Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression,” International Journal of Molecular Sciences 23, no. 1 (2021): 146.

[137] N. M. Abdel-Hamid and S. A. Abass, “Matrix Metalloproteinase Contribution in Management of Cancer Proliferation, Metastasis and Drug Targeting,” Molecular Biology Reports 48, no. 9 (2021): 6525-6538.

[138] J. Zheng, X. Li, A. He, et al., “In Situ Antigen-capture Strategies for Enhancing Dendritic Cell-mediated Anti-tumor Immunity,” Journal of Controlled Release 385 (2025): 113984.

[139] L. Hato, A. Vizcay, I. Eguren, et al., “Dendritic Cells in Cancer Immunology and Immunotherapy,” Cancers 16, no. 5 (2024): 981.

[140] T. Akinsipe, R. Mohamedelhassan, A. Akinpelu, et al., “Cellular Interactions in Tumor Microenvironment During Breast Cancer Progression: New Frontiers and Implications for Novel Therapeutics,” Frontiers in Immunology 15 (2024): 1302587.

[141] J. Y. Mun, S. H. Leem, J. H. Lee, and H. S. Kim, “Dual Relationship between Stromal Cells and Immune Cells in the Tumor Microenvironment,” Frontiers in Immunology 13 (2022): 864739.

[142] W. Zhang, H. Wang, M. Sun, et al., “CXCL5/CXCR2 axis in Tumor Microenvironment as Potential Diagnostic Biomarker and Therapeutic Target,” Cancer Communications 40, no. 2-3 (2020): 69-80.

[143] P. Miziak, M. Baran, E. Błaszczak, et al., “Estrogen Receptor Signaling in Breast Cancer,” Cancers 15, no. 19 (2023): 4689.

[144] Y. Arao and K. S. Korach, “The Physiological Role of Estrogen Receptor Functional Domains,” Essays in Biochemistry 65, no. 6 (2021): 867-875.

[145] T. Saha and K. E. Lukong, “Decoding Estrogen Receptor and GPER Biology: Structural Insights and Therapeutic Advances in ERα−Positive Breast Cancer,” Frontiers in Oncology 15 (2025): 1513225.

[146] T. Li, W. Feng, W. Yan, and T. Wang, “From Metabolic to Epigenetic: Insight Into Trained Macrophages in Atherosclerosis (Review),” Molecular Medicine Reports 30, no. 2 (2024): 145-2024.

[147] K. M. Poluri, K. Gulati, D. K. Tripathi, and N. Nagar, “Protein-Protein Interactions in Cancer,” Protein-Protein Interact (2023): 43-100, https://doi.org/10.1007/978-981-99-2423-3_2. Published online.

[148] C. A. Basset, E. Conway de Macario, L. G. Leone, A. J. L. Macario, and A. Leone, “The Chaperone System in Cancer Therapies: Hsp90,” Journal of Molecular Histology 54, no. 2 (2023): 105-118.

[149] P. Miziak, M. Baran, E. Błaszczak, et al., “Estrogen Receptor Signaling in Breast Cancer,” Cancers 15, no. 19 (2023): 4689.

[150] M. Z. I. Khan, M. Uzair, A. Nazli, and J. Z. Chen, “An Overview on Estrogen Receptors Signaling and Its Ligands in Breast Cancer,” European Journal of Medicinal Chemistry 241 (2022): 114658.

[151] S. Zheng, L. Wu, C. Fan, et al., “The Role of Gα Protein Signaling in the Membrane Estrogen Receptor-mediated Signaling,” Gynecological Endocrinology 37, no. 1 (2021): 2-9.

[152] X. Yang, D. Yang, X. Qi, X. Luo, and G. Zhang, “Endocrine Treatment Mechanisms in Triple-positive Breast Cancer: From Targeted Therapies to Advances in Precision Medicine,” Frontiers in Oncology 14 (2025): 1467033.

[153] A. Chimento, A. De Luca, P. Avena, et al., “Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers,” International Journal of Molecular Sciences 23, no. 3 (2022): 1242.

[154] K. Al-Shami, S. Awadi, A. Khamees, et al., “Estrogens and the Risk of Breast Cancer: A Narrative Review of Literature,” Heliyon 9, no. 9 (2023): e20224.

[155] A. Strillacci, P. Sansone, V. K. Rajasekhar, et al., “ERα-LBD, an Isoform of Estrogen Receptor Alpha, Promotes Breast Cancer Proliferation and Endocrine Resistance,” Npj Breast Cancer 8, no. 1 (2022): 1-16.

[156] A. Grinshpun, V. Chen, Z. M. Sandusky, S. W. Fanning, and R. Jeselsohn, “ESR1 activating Mutations: From Structure to Clinical Application,” Biochimica et Biophysica Acta: Reviews on Cancer 1878, no. 1 (2023): 188830.

[157] R. Ozyurt and B. Ozpolat, “Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies,” Cancers 14, no. 21 (2022): 5206.

[158] A. Sood, D. K. Lang, R. Kaur, B. Saini, and S. Arora, “Relevance of Aromatase Inhibitors in Breast Cancer Treatment,” Current Topics in Medicinal Chemistry 21, no. 15 (2021): 1319-1336.

[159] A. Das, K. J. Lavanya, K. K. Nandini, and V. Jaitak, “Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update,” Current Medicinal Chemistry 30, no. 29 (2022): 3287-3314.

[160] H. R. M. Rashdan and I. A. Shehadi, “Triazoles Synthesis & Applications as Nonsteroidal Aromatase Inhibitors for Hormone-Dependent Breast Cancer Treatment,” Heteroatom Chemistry 2022, no. 1 (2022): 5349279.

[161] N. Kim and K. E. Lukong, “Treating ER-positive Breast Cancer: A Review of the Current FDA-approved SERMs and SERDs and Their Mechanisms of Action,” Oncology Reports 19 (2025): 1564642.

[162] D. J. Hosfield, S. Weber, N. S. Li, et al., “Stereospecific Lasofoxifene Derivatives Reveal the Interplay Between Estrogen Receptor Alpha Stability and Antagonistic Activity in ESR1 Mutant Breast Cancer Cells,” Elife 11 (2022): e72512.

[163] L. Xu, Y. Xie, Q. Gou, et al., “HER2-targeted Therapies for HER2-positive Early-stage Breast Cancer: Present and Future,” Frontiers in Pharmacology 15 (2024): 1446414.

[164] I. Shin, “HER2 Signaling in Breast Cancer,” Advances in Experimental Medicine and Biology 1187 (2021): 53-79.

[165] R. Kavarthapu, R. Anbazhagan, and M. L. Dufau, “Crosstalk Between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer,” Cancers 13, no. 18 (2021): 4685.

[166] M. Zhu, M. Yu, Y. Meng, et al., “HER3 receptor and Its Role in the Therapeutic Management of Metastatic Breast Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 1-15.

[167] K. Zhu, X. Yang, H. Tai, X. Zhong, T. Luo, and H. Zheng, “HER2-targeted Therapies in Cancer: A Systematic Review,” Biomarker Research 12, no. 1 (2024): 1-17.

[168] M. Stanowicka-Grada and E. Senkus, “Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer,” Current Treatment Options in Oncology 24, no. 11 (2023): 1633-1650.

[169] X. Bai, P. Sun, X. Wang, et al., “Structure and Dynamics of the EGFR/HER2 Heterodimer,” Cell Discovery 9, no. 1 (2023): 1-16.

[170] N. Zhang and Y. Li, “Receptor Tyrosine Kinases: Biological Functions and Anticancer Targeted Therapy,” MedComm 4, no. 6 (2023): e446.

[171] T. Kawano, J. Inokuchi, M. Eto, M. Murata, and J. H. Kang, “Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer,” Cancers 14, no. 21 (2022): 5425.

[172] K. Zhu, Y. Wu, P. He, et al., “PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer,” Cells 11, no. 16 (2022): 2508.

[173] E. M. Serrano-López, T. Coronado-Parra, C. Marín-Vicente, et al., “Deciphering the Role and Signaling Pathways of PKCα in Luminal A Breast Cancer Cells,” International Journal of Molecular Sciences 23, no. 22 (2022): 14023.

[174] M. K. Kashyap, S. Roy, S. Jaiswal, et al., “Recent Prospectives of Cellular Signaling Role for Mammary Gland Carcinogenesis,” Anti-Cancer Agents in Medicinal Chemistry 25 (2025): 818-840.

[175] B. Kinnel, S. K. Singh, G. Oprea-Ilies, and R. Singh, “Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer,” Cancers 15, no. 4 (2023): 1320.

[176] Y. Peng, Y. Wang, C. Zhou, W. Mei, and C. Zeng, “PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?,” Frontiers in Oncology 12 (2022): 819128.

[177] I. Ahmad, M. Hoque, S. S. M. Alam, T. A. Zughaibi, and S. Tabrez, “Curcumin and Plumbagin Synergistically Target the PI3K/Akt/mTOR Pathway: A Prospective Role in Cancer Treatment,” International Journal of Molecular Sciences 24, no. 7 (2023): 6651.

[178] Y. He, M. M. Sun, G. G. Zhang, et al., “Targeting PI3K/Akt Signal Transduction for Cancer Therapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 1-17.

[179] A. B. S. Khorasani, N. Hafezi, M. J. Sanaei, F. Jafari-Raddani, A. Pourbagheri-Sigaroodi, and D. Bashash, “The PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: Review of Clinical Trials and Latest Advances,” Cell Biochemistry and Function 42, no. 3 (2024): e3998.

[180] A. S. Khatpe, A. K. Adebayo, C. A. Herodotou, B. Kumar, and H. Nakshatri, “Nexus Between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer,” Cancers 13, no. 3 (2021): 369.

[181] T. Y. Aytenfisu, H. M. Campbell, M. Chakrabarti, L. M. Amzel, and S. B. Gabelli, “Class I PI3K Biology,” Current Topics in Microbiology and Immunology 436 (2022): 3-49.

[182] C. W. Kim, J. M. Lee, and S. W. Park, “Divergent Roles of the Regulatory Subunits of Class IA PI3K,” Frontiers in Endocrinology (Lausanne) 14 (2023): 1152579.

[183] B. Thibault, F. Ramos-Delgado, and J. Guillermet-Guibert, “Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research,” Cancers 15, no. 3 (2023): 784.

[184] M. Yu, J. Chen, Z. Xu, et al., “Development and Safety of PI3K Inhibitors in Cancer,” Archives of Toxicology 97, no. 3 (2023): 635-650.

[185] G. Solinas and B. Becattini, “PI3K and AKT at the Interface of Signaling and Metabolism,” Current Topics in Microbiology and Immunology 436 (2022): 311-336.

[186] K. Yoshioka, “Class II Phosphatidylinositol 3-kinase Isoforms in Vesicular Trafficking,” Biochemical Society Transactions 49, no. 2 (2021): 893-901.

[187] C. A. Chu, Y. W. Wang, Y. L. Chen, et al., “The Role of Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 in the Pathogenesis of Human Cancer,” International Journal of Molecular Sciences 22, no. 20 (2021): 10964.

[188] S. M. Afify, A. K. K. Oo, G. Hassan, A. Seno, and M. Seno, “How Can We Turn the PI3K/AKT/mTOR Pathway Down? Insights Into Inhibition and Treatment of Cancer,” Expert Review of Anticancer Therapy 21, no. 6 (2021): 605-619.

[189] M. A. Galal, S. S. Alouch, B. S. Alsultan, et al., “Insulin Receptor Isoforms and Insulin Growth Factor-Like Receptors: Implications in Cell Signaling, Carcinogenesis, and Chemoresistance,” International Journal of Molecular Sciences 24, no. 19 (2023): 15006.

[190] P. K. Chaudhary and S. Kim, “An Insight Into GPCR and G-Proteins as Cancer Drivers,” Cells 10, no. 12 (2021): 3288.

[191] C. Cuesta, C. Arévalo-Alameda, and E. Castellano, “The Importance of Being PI3K in the RAS Signaling Network,” Genes 12, no. 7 (2021): 1094.

[192] F. Rascio, F. Spadaccino, M. T. Rocchetti, et al., “The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review,” Cancers 13, no. 16 (2021): 3949.

[193] Z. Ahmad and P. R. Somanath, “AKT Isoforms in the Immune Response in Cancer,” Current Topics in Microbiology and Immunology 436 (2022): 349-366.

[194] T. O. Omolekan, J. C. Chamcheu, C. Buerger, and S. Huang, “PI3K/AKT/mTOR Signaling Network in Human Health and Diseases,” Cells 13, no. 17 (2024): 1500.

[195] P. J. Tsai, Y. H. Lai, R. K. Manne, Y. S. Tsai, D. Sarbassov, and H. K. Lin, “Akt: A Key Transducer in Cancer,” Journal of Biomedical Science 29, no. 1 (2022): 1-17.

[196] H. Hua, H. Zhang, J. Chen, J. Wang, J. Liu, and Y. Jiang, “Targeting Akt in Cancer for Precision Therapy,” Journal of Hematology & Oncology 14, no. 1 (2021): 1-25.

[197] M. El-Tanani, H. Nsairat, A. A. Aljabali, et al., “Role of Mammalian Target of Rapamycin (mTOR) Signalling in Oncogenesis,” Life Sciences 323 (2023): 121662.

[198] A. Szwed, E. Kim, and E. Jacinto, “REGULATION and METABOLIC FUNCTIONS of mTORC1 and mTORC2,” Physiological Reviews 101, no. 3 (2021): 1371-1426.

[199] L. Kotelevets, É. Chastre, M. Noguchi, A. González-García, A. Garrido, and A. C. Carrera, “Targeting PTEN Regulation by Post Translational Modifications,” Cancers 14, no. 22 (2022): 5613.

[200] M. F. da Silva, A. A. Lins, M. C. Gomes, et al., “Anticancer Drug Discovery From Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway,” Current Medicinal Chemistry (2024): 31, https://doi.org/10.2174/0109298673325229240928040758.

[201] C. Dong, J. Wu, Y. Chen, J. Nie, and C. Chen, “Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer,” Frontiers in Pharmacology 12 (2021): 628690.

[202] H. Li, L. Prever, E. Hirsch, and F. Gulluni, “Targeting pi3k/Akt/Mtor Signaling Pathway in Breast Cancer,” Cancers (Basel) 13, no. 14 (2021): 3517.

[203] I. S. Hiremath, A. Goel, S. Warrier, A. P. Kumar, G. Sethi, and M. Garg, “The Multidimensional Role of the Wnt/β-catenin Signaling Pathway in human Malignancies,” Journal of Cellular Physiology 237, no. 1 (2022): 199-238.

[204] P. Song, Z. Gao, Y. Bao, et al., “Wnt/β-catenin Signaling Pathway in Carcinogenesis and Cancer Therapy,” Journal of Hematology & Oncology 17, no. 1 (2024): 1-30.

[205] A. Mahanujam and B. Student, “The Role of Beta-Catenin and the Wnt Signalling Pathway in Breast Cancer Initiation, Progression and Metastasis: A Literature Review,” Undergraduate Research in Natural and Clinical Science and Technology Journal 9, no. 2 (2025): 1-9.

[206] H. He, X. Shao, Y. Li, et al., “Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges,” Frontiers in Pharmacology 12 (2021): 675675.

[207] N. Zhang, H. Shen, B. Chen, et al., “The Recent Progress of Peptide Regulators for the Wnt/β-catenin Signaling Pathway,” Frontiers in Medicine 10 (2023): 1164656.

[208] X. Zhang, N. Dong, and X. Hu, “Wnt/β-catenin Signaling Inhibitors,” Current Topics in Medicinal Chemistry 23, no. 10 (2023): 880-896.

[209] X. Xu, M. Zhang, F. Xu, and S. Jiang, “Wnt Signaling in Breast Cancer: Biological Mechanisms, Challenges and Opportunities,” Molecular Cancer 19, no. 1 (2020): 1-35.

[210] Y. Zhang and X. Wang, “Targeting the Wnt/β-catenin Signaling Pathway in Cancer,” Journal of Hematology & Oncology 13, no. 1 (2020): 1-16.

[211] A. M. Bode, R. Morris, T. Zhang, K. T. Chuang, S. S. Chiou, and S. H. Hsu, “Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition,” Cancers 15, no. 13 (2023): 3338.

[212] B. Buyuk, S. Jin, and K. Ye, “Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis,” Cellular and Molecular Bioengineering 15, no. 1 (2022): 1-13.

[213] F. Nasser, N. Moussa, M. W. Helmy, and M. Haroun, “Dual Targeting of Notch and Wnt/β-catenin Pathways: Potential Approach in Triple-negative Breast Cancer Treatment,” Naunyn-Schmiedebergs Archives of Pharmacology 394, no. 3 (2021): 481-490.

[214] P. Merikhian, M. R. Eisavand, and L. Farahmand, “Triple-negative Breast Cancer: Understanding Wnt Signaling in Drug Resistance,” Cancer Cell International 21, no. 1 (2021): 1-8.

[215] F. I. Dimitrakopoulos, A. Kottorou, and A. Tzezou, “Endocrine Resistance and Epigenetic Reprogramming in Estrogen Receptor Positive Breast Cancer,” Cancer Letters 517 (2021): 55-65.

[216] Y. Liu, Y. Zou, Y. Ye, and Y. Chen, “Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer,” Cancer Medicine 13, no. 22 (2024): e70410.

[217] B. Huang, X. Lang, and X. Li, “The Role of IL-6/JAK2/STAT3 Signaling Pathway in Cancers,” Frontiers in Oncology 12 (2022): 1023177.

[218] T. M. Ayele, Z. T. Muche, A. B. Teklemariam, A. B. Kassie, and E. C. Abebe, “Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review,” Journal of Inflammation Research 15 (2022): 1349-1364.

[219] M. A. Samad, I. Ahmad, A. Hasan, et al., “STAT3 Signaling Pathway in Health and Disease,” MedComm 6, no. 4 (2025): e70152.

[220] Y. H. Dinakar, H. Kumar, S. L. Mudavath, R. Jain, R. Ajmeer, and V. Jain, “Role of STAT3 in the Initiation, Progression, Proliferation and Metastasis of Breast Cancer and Strategies to Deliver JAK and STAT3 Inhibitors,” Life Sciences 309 (2022): 120996.

[221] R. Y. Jiang, J. Y. Zhu, H. P. Zhang, et al., “STAT3: Key Targets of Growth-promoting Receptor Positive Breast Cancer,” Cancer Cell International 24, no. 1 (2024): 1-41.

[222] L. Long, X. Fei, L. Chen, L. Yao, and X. Lei, “Potential Therapeutic Targets of the JAK2/STAT3 Signaling Pathway in Triple-negative Breast Cancer,” Frontiers in Oncology 14 (2024): 1381251.

[223] M. Wang, M. Liu, C. Yang, Y. Hu, X. Liao, and Q. Liu, “Autophagy Modulation in Therapeutic Strategy of Breast Cancer Drug Resistance,” Journal of Cancer 15, no. 16 (2024): 5462.

[224] S. Q. To, R. S. Dmello, A. K. Richards, et al., “STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential,” Cancers 14, no. 2 (2022): 429.

[225] S. G. Manore, D. L. Doheny, G. L. Wong, and H. W. Lo, “IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment,” Frontiers in Oncology 12 (2022): 866014.

[226] F. Y. Gao, X. T. Li, K. Xu, R. T. Wang, and X. X. Guan, “c-MYC Mediates the Crosstalk Between Breast Cancer Cells and Tumor Microenvironment,” Cell Communication and Signaling 21, no. 1 (2023): 1-8.

[227] C. M. Neophytou, I. P. Trougakos, N. Erin, and P. Papageorgis, “Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance,” Cancers 13, no. 17 (2021): 4363.

[228] S. Singh, H. J. Gomez, S. Thakkar, S. P. Singh, and A. S. Parihar, “Overcoming Acquired Drug Resistance to Cancer Therapies Through Targeted STAT3 Inhibition,” International Journal of Molecular Sciences 24, no. 5 (2023): 4722.

[229] M. Sadrkhanloo, M. Entezari, S. Orouei, et al., “STAT3-EMT Axis in Tumors: Modulation of Cancer Metastasis, Stemness and Therapy Response,” Pharmacological Research 182 (2022): 106311.

[230] N. Fultang, M. Chakraborty, and B. Peethambaran, “Regulation of Cancer Stem Cells in Triple Negative Breast Cancer,” Cancer Drug Resistance 4, no. 2 (2021): 321.

[231] A. M. Abuzenadah, F. Al-Sayes, and S. S. Mahafujul Alam, “Elucidating Antiangiogenic Potential of Rauwolfia Serpentina: VEGFR-2 Targeting-Based Molecular Docking Study,” Evidence-Based Complement Altern Med 2022, no. 1 (2022): 6224666.

[232] Z. Kohandel, T. Farkhondeh, M. Aschner, A. M. Pourbagher-Shahri, and S. Samarghandian, “STAT3 pathway as a Molecular Target for Resveratrol in Breast Cancer Treatment,” Cancer cell international 21, no. 1 (2021): 1-9.

[233] N. Jiang, Y. Hu, M. Wang, Z. Zhao, and M. Li, “The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer,” Breast Cancer: Targets and Therapy 14 (2022): 291-309.

[234] A. Guha, K. K. Goswami, J. Sultana, et al., “Cancer Stem Cell-immune Cell Crosstalk in Breast Tumor Microenvironment: A Determinant of Therapeutic Facet,” Frontiers in immunology 14 (2023): 1245421.

[235] W. Chen, W. Wei, L. Yu, et al., “Mammary Development and Breast Cancer: A Notch Perspective,” Journal of Mammary Gland Biology and Neoplasia 26, no. 3 (2021): 309-320.

[236] P. Sen and S. S. Ghosh, “The Intricate Notch Signaling Dynamics in Therapeutic Realms of Cancer,” ACS Pharmacology & Translational Science 6, no. 5 (2023): 651-670.

[237] N. Sachan, V. Sharma, M. Mutsuddi, and A. Mukherjee, “Notch Signalling: Multifaceted Role in Development and Disease,” Febs Journal 291, no. 14 (2024): 3030-3059.

[238] A. Edwards and K. Brennan, “Notch Signalling in Breast Development and Cancer,” Frontiers in Cell and Developmental Biology 9 (2021): 692173.

[239] A. Chimento, M. D'amico, V. Pezzi, and F. De Amicis, “Notch Signaling in Breast Tumor Microenvironment as Mediator of Drug Resistance,” International Journal of Molecular Sciences 23, no. 11 (2022): 6296.

[240] K. Song and M. Farzaneh, “Signaling Pathways Governing Breast Cancer Stem Cells Behavior,” Stem Cell Research & Therapy 12, no. 1 (2021): 1-11.

[241] T. Baram, L. Rubinstein-Achiasaf, H. Ben-Yaakov, and A. Ben-Baruch, “Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy,” Frontiers in oncology 10 (2021): 614468.

[242] Y. Tian, P. Zhang, Y. Mou, et al., “Silencing Notch4 Promotes Tumorigenesis and Inhibits Metastasis of Triple-negative Breast Cancer via Nanog and Cdc42,” Cell Death Discovery 9, no. 1 (2023): 1-10.

[243] K. Sheva, S. Roy Chowdhury, N. Kravchenko-Balasha, and A. Meirovitz, “Molecular Changes in Breast Cancer Induced by Radiation Therapy,” International Journal of Radiation Oncology 120, no. 2 (2024): 465-481.

[244] Q. Shi, C. Xue, Y. Zeng, et al., “Notch Signaling Pathway in Cancer: From Mechanistic Insights to Targeted Therapies,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 1-37.

[245] M. Wu, J. Mi, G. X. Qu, et al., “Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation,” Cell Transplantation 33 (2024): 9636897241244943.

[246] J. Jing, Z. Wu, J. Wang, et al., “Hedgehog Signaling in Tissue Homeostasis, Cancers and Targeted Therapies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 1-33.

[247] G. Cong, X. Zhu, X. R. Chen, H. Chen, and W. Chong, “Mechanisms and Therapeutic Potential of the Hedgehog Signaling Pathway in Cancer,” Cell Death Discovery 11, no. 1 (2025): 1-12.

[248] A. Giammona, E. Crivaro, and B. Stecca, “Emerging Roles of Hedgehog Signaling in Cancer Immunity,” International Journal of Molecular Sciences 24, no. 2 (2023): 1321.

[249] C. Suchors and J. Kim, “Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer,” Cells 11, no. 16 (2022): 2523.

[250] J. Y. Chai, V. Sugumar, M. A. Alshawsh, et al., “The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis,” Biomed 9, no. 9 (2021): 1188.

[251] B. Sreeshma, M. A. Varshini, A. P. Patni, and A. Devi, “Unravelling the Crosstalk of Hedgehog With Wnt, Notch and TGF-β Signaling Pathways,” Stem Cells Signal Pathways (2024): 181-203, https://doi.org/10.1016/B978-0-443-18800-8.00001-0.

[252] J. Kuehn, N. A. Espinoza-Sanchez, F. Teixeira, et al., “Prognostic Significance of Hedgehog Signaling Network-related Gene Expression in Breast Cancer Patients,” Journal of Cellular Biochemistry 122, no. 5 (2021): 577-597.

[253] A. García-Martínez, A. Pérez-Balaguer, F. Ortiz-Martínez, et al., “Hedgehog Gene Expression Patterns Among Intrinsic Subtypes of Breast Cancer: Prognostic Relevance,” Pathology - Research and Practice 223 (2021): 153478.

[254] M. Li, T. Guo, J. Lin, et al., “Curcumin Inhibits the Invasion and Metastasis of Triple Negative Breast Cancer via Hedgehog/Gli1 Signaling Pathway,” Journal of Ethnopharmacology 283 (2022): 114689.

[255] E. H. Joo, S. Kim, D. Park, et al., “Migratory Tumor Cells Cooperate With Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer,” International Journal of Molecular Sciences 25, no. 11 (2024): 5876.

[256] T. Zhu, J. Zheng, W. Zhuo, et al., “ETV4 promotes Breast Cancer Cell Stemness by Activating Glycolysis and CXCR4-mediated Sonic Hedgehog Signaling,” Cell Death Discovery 7, no. 1 (2021): 1-15.

[257] J. Liu, Y. Peng, and W. Wei, “Cell Cycle on the Crossroad of Tumorigenesis and Cancer Therapy,” Trends in Cell Biology 32, no. 1 (2022): 30-44.

[258] M. G. Koliopoulos and C. Alfieri, “Cell Cycle Regulation by Complex Nanomachines,” Febs Journal 289, no. 17 (2022): 5100-5120.

[259] H. K. Matthews, C. Bertoli, and R. A. M. de Bruin, “Cell Cycle Control in Cancer,” Nature Reviews Molecular Cell Biology 23, no. 1 (2021): 74-88.

[260] S. Ghafouri-Fard, T. Khoshbakht, B. M. Hussen, et al., “A Review on the Role of Cyclin Dependent Kinases in Cancers,” Cancer cell international 22, no. 1 (2022): 1-69.

[261] Nilmani, M. D'costa, A. Bothe, et al., “CDK Regulators—Cell Cycle Progression or Apoptosis—Scenarios in Normal Cells and Cancerous Cells,” Advances in Protein Chemistry and Structural Biology 135 (2023): 125-177.

[262] R. Janostiak, A. Torres-Sanchez, F. Posas, and E. de Nadal, “Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies,” Cancers 14, no. 5 (2022): 1265.

[263] P. Łukasik, M. Załuski, and I. Gutowska, “Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review,” International Journal of Molecular Sciences 22, no. 6 (2021): 2935.

[264] X. B. Liang, Z. C. Dai, R. Zou, J. X. Tang, and C. W. Yao, “The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases,” International Journal of Molecular Sciences 24, no. 17 (2023): 13558.

[265] R. Roufayel, R. Mezher, and K. B. Storey, “The Role of Retinoblastoma Protein in Cell Cycle Regulation: An Updated Review,” Current Molecular Medicine 21, no. 8 (2021): 620-629.

[266] A. Fassl, Y. Geng, and P. Sicinski, “CDK4 and CDK6 Kinases: From Basic Science to Cancer Therapy,” Science (80-) 375, no. 6577 (2022), https://doi.org/10.1126/SCIENCE.ABC1495/ASSET/08D57D30-C4DF-480D-8060-8367091AD155/ASSETS/IMAGES/LARGE/SCIENCE.ABC1495-FA.JPG.

[267] S. Goel, J. S. Bergholz, and J. J. Zhao, “Targeting CDK4 and CDK6 in Cancer,” Nature Reviews Cancer 22, no. 6 (2022): 356-372.

[268] S. Kim, J. Armand, and A. Safonov, “Sequential Activation of E2F via Rb Degradation and c-Myc Drives Resistance to CDK4/6 Inhibitors in Breast Cancer,” Cell reports 42, no. 11 (2023): 113198.

[269] Z. Guo, R. W. Dong, Y. Wu, S. Dong, and S. K. Alahari, “Cyclin-dependent Kinase 4 and 6 Inhibitors in Breast Cancer Treatment,” Oncogene 44, no. 17 (2025): 1135-1152.

[270] A. K. Siraj, S. K. Parvathareddy, P. Annaiyappanaidu, et al., “High Expression of Cyclin d1 Is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer,” OncoTargets and Therapy 14 (2021): 3309-3318.

[271] G. Gomatou, I. Trontzas, S. Ioannou, M. Drizou, N. Syrigos, and E. Kotteas, “Mechanisms of Resistance to Cyclin-dependent Kinase 4/6 Inhibitors,” Molecular Biology Reports 48, no. 1 (2021): 915-925.

[272] S. Timilsina. TARGETING FORKHEAD BOX M1 AS A NOVEL APPROACH TO INHIBIT BREAST CANCER GROWTH AND PROGRESSION. Published online 2022.

[273] B. S. Katzenellenbogen, V. S. Guillen, and J. A. Katzenellenbogen, “Targeting the Oncogenic Transcription Factor FOXM1 to Improve Outcomes in all Subtypes of Breast Cancer,” Breast Cancer Research 25, no. 1 (2023): 1-11.

[274] S. Dilmac, Z. Hamurcu, and B. Ozpolat, “Therapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers,” Cancers 16, no. 22 (2024): 3823.

[275] G. Sher, T. Masoodi, K. Patil, et al., “Dysregulated FOXM1 Signaling in the Regulation of Cancer Stem Cells,” Seminars in Cancer Biology 86 (2022): 107-121.

[276] K. Krupa, A. Liszcz-Tymoszuk, N. Czerw, et al., “CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status,” Cancers 17, no. 6 (2025): 1039.

[277] L. Morrison, S. Loibl, and N. C. Turner, “The CDK4/6 Inhibitor Revolution — a Game-changing Era for Breast Cancer Treatment,” Nature reviews Clinical oncology 21, no. 2 (2023): 89-105.

[278] Y. Li, L. Li, Q. Du, Y. Li, H. Yang, and Q. Li, “Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER-2− ABC Patients: A Systematic Review and Meta-Analysis,” Cancer Investigation 39, no. 5 (2021): 369-378.

[279] B. Cetin, C. A. Wabl, and O. Gumusay, “CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer,” Futur Oncology 18, no. 9 (2022): 1143-1157.

[280] A. C. Watt and S. Goel, “Cellular Mechanisms Underlying Response and Resistance to CDK4/6 Inhibitors in the Treatment of Hormone Receptor-positive Breast Cancer,” Breast Cancer Research 24, no. 1 (2022): 1-11.

[281] G. T. Gallanis, R. I. Pericas, A. T. Riegel, and P. R. Pohlmann, “An Evaluation of palbociclib as a Breast Cancer Treatment Option: A Current Update,” Expert Opinion on Pharmacotherapy 22, no. 3 (2021): 281-290.

[282] D. Konar, S. Maru, S. Kar, and K. Kumar, “Synthesis and Clinical Development of Palbociclib: An Overview,” Medicinal Chemistry (Los Angeles) 18, no. 1 (2020): 2-25.

[283] Y. Li, W. Li, C. Gong, et al., “A Multicenter Analysis of Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on palbociclib in HR+/HER2− Metastatic Breast Cancer,” Therapeutic Advances in Medical Oncology 13 (2021): 17588359211022890.

[284] F. C. Bidard, A.-C. Hardy-Bessard, F. Dalenc, et al., “Switch to Fulvestrant and Palbociclib versus no Switch in Advanced Breast Cancer With Rising ESR1 Mutation During Aromatase Inhibitor and Palbociclib Therapy (PADA-1): A Randomised, Open-label, Multicentre, Phase 3 Trial,” The Lancet Oncology 23, no. 11 (2022): 1367-1377.

[285] N. Martínez-Jañez, M. B. Ezquerra, and L. M. Manso Sanchez, “First-line Therapy With palbociclib in Patients With Advanced HR+/HER2− Breast Cancer: The Real-life Study PALBOSPAIN,” Breast Cancer Research and Treatment 206, no. 2 (2024): 317-328.

[286] W. Lin, Y. Zeng, L. Weng, J. Yang, and W. Zhuang, “Comparative Analysis of Adverse Events Associated With CDK4/6 Inhibitors Based on FDA's Adverse Event Reporting System: A Case Control Pharmacovigilance Study,” BMC Pharmacol Toxicology 25, no. 1 (2024): 1-11.

[287] Q. Cheng, X. Shi, Y. Zhao, S. Zou, and M. Sun, “Post-marketing Safety Concerns With palbociclib: A Disproportionality Analysis of the FDA Adverse Event Reporting System,” Expert Opinion on Drug Safety 23, no. 5 (2024): 637-648.

[288] C. T. Brain, R. Chopra, S. Kim, S. Howard, and M. J. Sung, “The Discovery of Kisqali® (Ribociclib): A CDK4/6 Inhibitor for the Treatment of HR+/HER2− Advanced Breast Cancer,” Success Drug Discovery 5 (2021): 273-289.

[289] Y. S. Lu, E. Mahidin, H. Azim, et al., “Final Results of RIGHT Choice: Ribociclib plus Endocrine Therapy versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer,” Journal of Clinical Oncology 42, no. 23 (2024): 2812-2821.

[290] C. A. Peuker, S. Yaghobramzi, C. Grunert, et al., “Treatment With ribociclib Shows Favourable Immunomodulatory Effects in Patients With Hormone Receptor-positive Breast Cancer—findings From the RIBECCA Trial,” European Journal of Cancer 162 (2022): 45-55.

[291] V. Lambert, S. Kane, B. Howidi, et al., “Systematic Literature Review of Real-world Evidence for Treatments in HR+/HER2- second-line LABC/mBC After First-line Treatment With CDK4/6i,” BMC cancer 24, no. 1 (2024): 1-12.

[292] J. He, J. Zhao, S. Dai, and S. Li. Comparison of Treatment-Related Adverse Events of CDK4/6 Inhibitors Combined with Endocrine Therapy Versus Endocrine Therapy in HR, HER2- Breast Cancer: A Meta-Analysis. Published online 2023, https://doi.org/10.2139/SSRN.4608009.

[293] J. Shen, P. Luo, and J. Xu, “Adverse Event Profiles of CDK4/6 Inhibitors: Data Mining and Disproportionality Analysis of the FDA Adverse Event Reporting System,” Therapeutic Advances in Drug Safety 15 (2024): 20420986241278498.

[294] S. A. Wander, N. O'brien, and L. M. Litchfield, “Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib,” The Oncologist 27, no. 10 (2022): 811-821.

[295] R. Benot-Dominguez, A. Cimini, D. Barone, A. Giordano, and F. Pentimalli, “The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?,” Cancers 14, no. 11 (2022): 2709.

[296] F. Raheem, H. Ofori, L. Simpson, and V. Shah, “Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2− Early Breast Cancer,” Annals of Pharmacotherapy 56, no. 11 (2022): 1258-1266.

[297] S. M. Tolaney, M. Beeram, J. T. Beck, et al., “Abemaciclib in Combination with Endocrine Therapy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study,” Frontiers in oncology 11 (2022): 810023.

[298] C. E. Onesti and G. Jerusalem, “CDK4/6 inhibitors in Breast Cancer: Differences in Toxicity Profiles and Impact on Agent Choice. A Systematic Review and Meta-analysis,” Expert Review of Anticancer Therapy 21, no. 3 (2021): 283-298.

[299] Y. Shu, L. Wang, Y. Ding, and Q. Zhang, “Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment,” Drug Safety 46, no. 9 (2023): 881-895.

[300] H. S. Rugo, J. Huober, J. A. García-Sáenz, et al., “Management of Abemaciclib-Associated Adverse Events in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3,” The Oncologist 26, no. 1 (2021): e53-e65.

[301] S. Wu, J. Xu, Y. Ma, G. Liang, J. Wang, and T. Sun, “Advances in the Mechanism of CDK4/6 Inhibitor Resistance in HR+/HER2− Breast Cancer,” Therapeutic Advances in Medical Oncology 16 (2024): 17588359241282499.

[302] A. Shanabag, J. Armand, E. Son, and H. W. Yang, “Targeting CDK4/6 in Breast Cancer,” Experimental & Molecular Medicine 57, no. 2 (2025): 312-322.

[303] Y. S. Lu, S. A. Im, M. Colleoni, et al., “Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial,” Clinical Cancer Research 28, no. 5 (2022): 851-859.

[304] L. Provenzano, M. V. Dieci, G. Curigliano, et al., “Real-world Effectiveness Comparison of First-line Palbociclib, Ribociclib or Abemaciclib plus Endocrine Therapy in Advanced HR-positive/HER2-negative BC Patients: Results From the Multicenter PALMARES-2 Study,” Annals of Oncology 36, no. 7 (2025): 762-774.

[305] D. Pu, D. Xu, Y. Wu, et al., “Efficacy of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2− Breast Cancer: An Umbrella Review,” Journal of Cancer Research and Clinical Oncology 150, no. 1 (2025): 1-14.

[306] X. Wang, S. Zhao, Q. Xin, Y. Zhang, K. Wang, and M. Li, “Recent Progress of CDK4/6 Inhibitors' current Practice in Breast Cancer,” Cancer Gene Therapy 31, no. 9 (2024): 1283-1291.

[307] F. Giugliano, C. De Angelis, B. Pistilli, et al., “Overcoming Resistance to CDK4/6 Inhibitors in Hormone Receptor Positive, HER2 Negative Breast Cancer: Innovative Combinations and Emerging Strategies,” Cancer Treatment Reviews 139 (2025): 102980.

[308] P. Neven, P. A. Fasching, S. Chia, et al., “Updated Overall Survival From the MONALEESA-3 Trial in Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Receiving First-line Ribociclib plus Fulvestrant,” Breast Cancer Research 25, no. 1 (2023): 1-10.

[309] E. V. Klocker, D. Egle, R. Bartsch, G. Rinnerthaler, and M. Gnant, “Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer,” Drugs 85, no. 2 (2025): 149-169.

[310] Y. Chen, Y. Xie, D. Sang, et al., “Real-world Comparison of palbociclib, abemaciclib, and dalpiciclib as First-line Treatments for Chinese HR+/HER2−Metastatic Breast Cancer Patients: A Multicenter Study (YOUNGBC-28),” Therapeutic Advances in Medical Oncology 16 (2024): 17588359241302018.

[311] Z. M. Shao, J. Hao, S. Wang, et al., “Dalpiciclib (Dalp) plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2- early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial,” Journal of Clinical Oncology 43, no. 16_suppl (2025): 515-515.

[312] X. Hu, Z. Tao, S. Wang, et al., “320MO Tibremciclib (BPI-16350) plus Fulvestrant in Patients With HR+/HER2- advanced Breast Cancer After Progressing on Endocrine Therapy: A Randomized, Multicenter, Double-blind, Phase III Study,” Annals of Oncology 35 (2024): S349.

[313] Z. Tao, J. Zhang, Q. Zheng, et al., “Abstract PS2-02: Tibremciclib (BPI-16350) plus Fulvestrant versus Placebo plus Fulvestrant for Patients With HR+/HER2- advanced Breast Cancer After Progressing on Endocrine Therapy: Updated Analysis of the Phase III Study,” Clinical Cancer Research 31, no. 12_Supplement (2025): PS2-02.

[314] R. S. Finn, K. Boer, I. Bondarenko, et al., “Overall Survival Results From the Randomized Phase 2 Study of palbociclib in Combination With letrozole versus letrozole Alone for First-line Treatment of ER+/HER2− Advanced Breast Cancer (PALOMA-1, TRIO-18),” Breast Cancer Research and Treatment 183, no. 2 (2020): 419-428.

[315] V. Diéras, N. Harbeck, A. A. Joy, et al., “Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial,” The Oncologist 24, no. 12 (2019): 1514-1525.

[316] M. Cristofanilli, H. S. Rugo, S. A. Im, et al., “Overall Survival With Palbociclib and Fulvestrant in Women With HRþ/HER2¯ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study,” Clinical Cancer Research 28, no. 16 (2022): 3433-3442.

[317] P. Neven, H. S. Rugo, S. M. Tolaney, et al., “Abemaciclib plus fulvestrant in Hormone Receptor-positive, human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 Trial,” Breast Cancer Research 23, no. 1 (2021): 1-10.

[318] M. P. Goetz, M. Toi, J. Huober, et al., “Abemaciclib plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy for HR+, HER2− Advanced Breast Cancer: Final Overall Survival Results of MONARCH 3,” Annals of Oncology 35, no. 8 (2024): 718-727.

[319] G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, et al., “Updated Results From MONALEESA-2, a Phase III Trial of First-line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer,” Annals of Oncology 29, no. 7 (2018): 1541-1547.

[320] D. J. Slamon, P. Neven, S. Chia, et al., “Corrigendum to ‘Ribociclib plus Fulvestrant for Postmenopausal’ Women With Hormone Receptor-positive, human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the Phase III Randomized MONALEESA-3 Trial: Updated Overall Survival,” Annals of Oncology 32, no. 10 (2021): 1307, https://doi.org/10.1016/j.annonc.2021.07.011.

[321] Y. S. Lu, S. A. Im, M. Colleoni, et al., “Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial,” Clinical Cancer Research 28, no. 5 (2022): 851-859.

[322] P. Zhang, Q. Y. Zhang, X. Hu, et al., “229P Dalpiciclib plus Fulvestrant in HR+/HER2− Advanced Breast Cancer (ABC): Updated Analysis From the Phase III DAWNA-1 Trial,” Annals of Oncology 33 (2022): S642-S643.

[323] P. Zhang, Q. Zhang, Z. Tong, et al., “Dalpiciclib plus Letrozole or Anastrozole versus Placebo plus Letrozole or Anastrozole as First-line Treatment in Patients With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer (DAWNA-2): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 24, no. 6 (2023): 646-657.

[324] I. M. Stanciu, A. I. Parosanu, and C. Nitipir, “An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials,” Biomol 13, no. 9 (2023): 1422.

[325] I. Gomes, C. Abreu, L. Costa, and S. Casimiro, “The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer,” Cancers 15, no. 19 (2023): 4835.

[326] M. Palafox, L. Monserrat, M. Bellet, et al., “High p16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER+ Breast Cancer,” Nature Communications 13, no. 1 (2022): 1-20.

[327] Y. Xue and J. Zhai, “Strategy of Combining CDK4/6 Inhibitors With Other Therapies and Mechanisms of Resistance,” International Journal of Clinical and Experimental Pathology 17, no. 7 (2024): 189.

[328] N. Sobhani, A. Fassl, G. Mondani, D. Generali, and T. Otto, “Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer,” Cells 10, no. 2 (2021): 293.

[329] M. M. Abu-Khalaf, K. Alex Hodge, C. Hatzis, et al., “AKT/mTOR Signaling Modulates Resistance to Endocrine Therapy and CDK4/6 Inhibition in Metastatic Breast Cancers,” Npj Precis Oncology 7, no. 1 (2023): 1-12.

[330] M. J. Rodriguez, M. C. Perrone, M. Riggio, et al., “Targeting mTOR to Overcome Resistance to Hormone and CDK4/6 Inhibitors in ER-positive Breast Cancer Models,” Scientific Reports 13, no. 1 (2023): 1-15.

[331] C. Belli, M. Repetto, S. Anand, C. Porta, V. Subbiah, and G. Curigliano, “The Emerging Role of PI3K Inhibitors for Solid Tumour Treatment and Beyond,” British Journal of Cancer 128, no. 12 (2023): 2150-2162.

[332] P. Narayan, T. M. Prowell, J. J. Gao, et al., “FDA Approval Summary: Alpelisib plus Fulvestrant for Patients With Hr-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer,” Clinical Cancer Research 27, no. 7 (2021): 1842-1849.

[333] A. Mavratzas and F. Marmé, “Alpelisib in the Treatment of Metastatic HR+ Breast Cancer With PIK3CA Mutations,” Futur Oncology 17, no. 1 (2021): 13-36.

[334] F. Leenhardt, M. Alexandre, and W. Jacot, “Alpelisib for the Treatment of PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer,” Expert Opinion on Pharmacotherapy 22, no. 6 (2021): 667-675.

[335] K. Jhaveri, D. Juric, Y. S. Yap, et al., “A Phase i Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients With Estrogen Receptor-positive Breast Cancer,” Clinical Cancer Research 27, no. 21 (2021): 5760-5770.

[336] F. André, E. M. Ciruelos, D. Juric, et al., “Alpelisib plus Fulvestrant for PIK3CA-mutated, Hormone Receptor-positive, human Epidermal Growth Factor Receptor-2-negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1,” Annals of Oncology 32, no. 2 (2021): 208-217.

[337] Y. Lin, X. Zheng, Y. Chen, Q. Nian, L. Lin, and M. Chen, “A Real-world Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for alpelisib,” Heliyon 10, no. 6 (2024): e27529.

[338] Y. Li, H. Li, and Z. Xiang, “Alpelisib-related Adverse Events: The FDA Adverse Event Reporting System Database (FAERS) Pharmacovigilance Study,” Heliyon 10, no. 6 (2024): 2405-8440.

[339] E. J. Hanan, M. G. Braun, R. A. Heald, et al., “Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα,” Journal of Medicinal Chemistry 65, no. 24 (2022): 16589-16621.

[340] P. L. Bedard, K. L. Jhaveri, M. K. Accordino, et al., “Inavolisib plus Letrozole or Fulvestrant in PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Advanced or Metastatic Breast Cancer (GO39374): An Open-label, Multicentre, Dose-escalation and Dose-expansion Phase 1/1b Study,” European Journal of Cancer 221 (2025): 115397.

[341] N. C. Turner, S. A. Im, C. Saura, et al., “Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer,” New England Journal of Medicine 391, no. 17 (2024): 1584-1596.

[342] G. Nader-Marta, S. M. Tolaney, and E. L. Mayer, “Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations,” JCO Oncology Advances 2, no. 2 (2025), https://doi.org/10.1200/OA-25-00041.

[343] D. Juric, K. Kalinsky, N. C. Turner, et al., “First-line inavolisib/Placebo + Palbociclib + Fulvestrant (Inavo/Pbo+Palbo+Fulv) in Patients (pts) With PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced/Metastatic Breast Cancer Who Relapsed During/Within 12 Months (mo) of Adjuvant Endocrine Therapy Completion: INAVO120 Phase III Randomized Trial Additional Analyses,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 1003-1003.

[344] K. L. Jhaveri, S. A. Im, C. Saura, et al., “Overall Survival With Inavolisib in PIK3CA -Mutated Advanced Breast Cancer,” New England Journal of Medicine 393, no. 2 (2025): 151-161. Published online July 10, 2025.

[345] H. A. Blair, “Inavolisib: First Approval,” Drugs 85, no. 2 (2025): 271-278.

[346] V. Gambardella, M. K. Accordino, P. L. Bedard, et al., “Safety Overview and Management of inavolisib Alone and in Combination Therapies in PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer (GO39374),” ESMO Open 10, no. 7 (2025): 105303.

[347] K. Jhaveri, M. T. Chang, D. Juric, et al., “Phase I Basket Study of taselisib, an Isoform-selective PI3K Inhibitor, in Patients With PIK3CA-mutant Cancers,” Clinical Cancer Research 27, no. 2 (2021): 447-459.

[348] R. Mishra, H. Patel, S. Alanazi, M. K. Kilroy, and J. T. Garrett, “PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects,” International Journal of Molecular Sciences 22, no. 7 (2021): 3464.

[349] D. A. Sabbah, R. Hajjo, S. K. Bardaweel, and H. A. Zhong, “Phosphatidylinositol 3-kinase (PI3K) Inhibitors: A Recent Update on Inhibitor Design and Clinical Trials (2016-2020),” Expert Opinion on Therapeutic Patents 31, no. 10 (2021): 877-892.

[350] J. Pascual, J. S. J. Lim, I. R. Macpherson, et al., “Triplet Therapy With Palbociclib, Taselisib, and Fulvestrant in pik3ca-mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-mutant Solid Cancers,” Cancer discovery 11, no. 1 (2021): 92-107.

[351] S. Dent, J. Cortés, Y. H. Im, et al., “Phase III Randomized Study of taselisib or Placebo With Fulvestrant in Estrogen Receptor-positive, PIK3CA-mutant, HER2-negative, Advanced Breast Cancer: The SANDPIPER Trial,” Annals of Oncology 32, no. 2 (2021): 197-207.

[352] K. S. Shan, A. Bonano-Rios, N. W. Y. Theik, A. Hussein, and M. Blaya, “Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway Across Various Cancers,” International Journal of Molecular Sciences 25, no. 4 (2024): 1973.

[353] A. Bertucci, F. Bertucci, and A. Gonçalves, “Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements,” Cancers 15, no. 5 (2023): 1416.

[354] A. Andrikopoulou, S. Chatzinikolaou, E. Panourgias, et al., “The Emerging Role of capivasertib in Breast Cancer,” The Breast 63 (2022): 157-167.

[355] K. A. Pervanidis, G. D. D'Angelo, J. Weisner, S. Brandherm, and D. Rauh, “Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises,” Journal of Medicinal Chemistry 67, no. 8 (2024): 6052-6063.

[356] M. Oliveira, H. S. Rugo, S. J. Howell, et al., “Capivasertib and fulvestrant for Patients With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer (CAPItello-291): Patient-reported Outcomes From a Phase 3, Randomised, Double-blind, Placebo-controlled Trial,” The Lancet Oncology 25, no. 9 (2024): 1231-1244.

[357] N. C. Turner, M. Oliveira, S. J. Howell, et al., “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 388, no. 22 (2023): 2058-2070.

[358] S. J. Howell, A. Casbard, M. Carucci, et al., “Fulvestrant plus capivasertib versus Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-positive, HER2-negative Breast Cancer (FAKTION): Overall Survival, Updated Progression-free Survival, and Expanded Biomarker Analysis From a Randomised, Phase 2 Trial,” The Lancet Oncology 23, no. 7 (2022): 851-864.

[359] N. C. Turner, E. Alarcón, A. C. Armstrong, et al., “BEECH: A Dose-finding Run-in Followed by a Randomised Phase II Study Assessing the Efficacy of AKT Inhibitor capivasertib (AZD5363) Combined With paclitaxel in Patients With Estrogen Receptor-positive Advanced or Metastatic Breast Cancer, and in a PIK3CA Mutant Sub-population,” Annals of Oncology 30, no. 5 (2019): 774-780.

[360] M. Oliveira, H. S. Rugo, S. J. Howell, et al., “187O Capivasertib and Fulvestrant for Patients (pts) With Aromatase Inhibitor (AI)-resistant HR+/HER2- advanced Breast Cancer (ABC): Subgroup Analyses From the Phase III CAPItello-291 Trial,” ESMO Open 8, no. 1 (2023): 101376.

[361] A. Dilawari, J. Buturla, C. Osgood, et al., “US Food and Drug Administration Approval Summary: Capivasertib with Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alterations,” Journal of Clinical Oncology 42, no. 34 (2024): 4103-4113.

[362] H. Rugo, B. Pistilli, J. Collins, et al., “Abstract PO2-19-10: CAPItello-292 Phase 3: An Open-label, Randomized Study of Capivasertib, Fulvestrant, and Investigator's Choice of CDK4/6 Inhibitor (palbociclib or ribociclib) in HR+/HER2- advanced Breast Cancer,” Cancer Research 84, no. 9_Supplement (2024): PO2-19-10.

[363] M. Shirley, “Capivasertib: First Approval,” Drugs 84, no. 3 (2024): 337-346.

[364] Z. Qureshi, F. Altaf, M. Khanzada, Z. Zaheer, E. Fatima, and M. Bakhtiar, “Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer,” Current Problems in Cancer 51 (2024): 101114.

[365] G. I. Shapiro, P. LoRusso, D. C. Cho, et al., “A Phase Ib Open-label Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in Patients With Locally Advanced or Metastatic Solid Tumors,” Investigational New Drugs 39, no. 1 (2021): 163-174.

[366] D. Iacopetta, J. Ceramella, N. Baldino, M. S. Sinicropi, and A. Catalano, “Targeting Breast Cancer: An Overlook on Current Strategies,” International Journal of Molecular Sciences 24, no. 4 (2023): 3643.

[367] L. Li, Y. Guo, Y. Lu, et al., “An Updated Patent Review of AKT Inhibitors (2020 - present),” Expert Opinion on Therapeutic Patents 33, no. 9 (2023): 549-564.

[368] S. Bose and K. Kalinsky, “Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient with an AKT1 E17K Mutant Metastatic Breast Cancer,” Clinical Breast Cancer 21, no. 3 (2021): e150-e153.

[369] R. Dent, S. B. Kim, M. Oliveira, et al., “IPATunity130: A Pivotal Randomized Phase III Trial Evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered Advanced Triple-negative (TN) or Hormone Receptor-positive HER2-negative (HR+/HER2-) Breast Cancer (BC),” Journal of Clinical Oncology 36, no. 15_suppl (2018): TPS1117-TPS1117.

[370] N. Turner, R. A. Dent, and J. O'Shaughnessy, “Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered Hormone Receptor-positive HER2-negative Advanced Breast Cancer: Primary Results From Cohort B of the IPATunity130 Randomized Phase 3 Trial,” Breast Cancer Research and Treatment 191, no. 3 (2022): 565-576.

[371] S. K. L. Chia, A. D. Redfern, J. P. M. Ayoub, et al., “A Double-blind Placebo Controlled Randomized Phase III Trial of fulvestrant and ipatasertib as Treatment for Advanced HER2-negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor: The CCTG/BCT MA.40/FINER Study (NCT04650581),” Journal of Clinical Oncology 43, no. 17_suppl (2025), https://doi.org/10.1200/JCO.2025.43.17_SUPPL.LBA1005.

[372] A. F. C. Okines, J. Braybrooke, I. R. MacPherson, et al., “Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With Addition of ipatasertib in Metastatic ER+/HER2- breast Cancer Patients Without Circulating Tumour (ct) DNA Suppression (FAIM),” Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1111-TPS1111.

[373] Y. Yuan, S. E. Yost, Y. Cui, et al., “Phase I Trial of Ipatasertib plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer,” The Oncologist 28, no. 7 (2023): e498-e507.

[374] E. S. Ali, K. Mitra, S. Akter, et al., “Recent Advances and Limitations of mTOR Inhibitors in the Treatment of Cancer,” Cancer cell international 22, no. 1 (2022): 1-16.

[375] Z. M. Shao, L. Cai, S. Wang, et al., “BOLERO-5: A Phase II Study of Everolimus and Exemestane Combination in Chinese Post-menopausal Women With ER + /HER2- advanced Breast Cancer,” Discovery Oncology 15, no. 1 (2024): 1-12.

[376] M. Piccart, G. N. Hortobagyi, M. Campone, et al., “Everolimus plus exemestane for Hormone-receptor-positive, human Epidermal Growth Factor Receptor-2-negative Advanced Breast Cancer: Overall Survival Results From BOLERO-2,” Annals of Oncology 25, no. 12 (2014): 2357-2362.

[377] M. Royce, C. Villanueva, M. Ozguroglu, et al., “BOLERO-4: Phase 2 Trial of First-line Everolimus (EVE) plus Letrozole (LET) in Estrogen Receptor-positive (ER+), human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (BC),” Annals of Oncology 27 (2016): vi68.

[378] M. E. Çakmak, “Drug Reaction With Eosinophilia and Systemic Symptom Syndrome due to Everolimus: A Case Report,” Annals of Dermatology 35, no. Suppl 2 (2023): S187.

[379] D. Starks, L. Rojas-Espaillat, T. Meissner, et al., “A Phase 1 Evaluation of the Safety and Tolerability of niraparib in Combination With everolimus in Advanced Ovarian and Breast Cancers,” Cancer medicine 12, no. 18 (2023): 18654-18665.

[380] S. Rossetti, A. Broege, A. Sen, et al., “Gedatolisib Shows Superior Potency and Efficacy versus Single-node PI3K/AKT/mTOR Inhibitors in Breast Cancer Models,” Npj Breast Cancer 10, no. 1 (2024): 1-15.

[381] R. M. Layman, H. S. Han, H. S. Rugo, et al., “Gedatolisib in Combination With palbociclib and Endocrine Therapy in Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: Results From the Dose Expansion Groups of an Open-label, Phase 1b Study,” The Lancet Oncology 25, no. 4 (2024): 474-487.

[382] R. Layman, R. Wesolowski, H. Han, et al., “Abstract PD13-02: Phase Ib Expansion Study of gedatolisib in Combination With Palbociclib and Endocrine Therapy in Women With ER+ Metastatic Breast Cancer,” Cancer Research 82, no. 4_Supplement (2022): PD13-PD22.

[383] S. A. Hurvitz, F. Andre, M. Cristofanilli, et al., “A Phase 3 Study of gedatolisib plus Fulvestrant With and Without Palbociclib in Patients With HR+/HER2- advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor plus a Nonsteroidal Aromatase Inhibitor (VIKTORIA-1),” Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1118-TPS1118.

[384] S. M. Swain, M. Shastry, and E. Hamilton, “Targeting HER2-positive Breast Cancer: Advances and Future Directions,” Nature Reviews Drug Discovery 22, no. 2 (2022): 101-126.

[385] C. S. Wynn and S. C. Tang, “Anti-HER2 Therapy in Metastatic Breast Cancer: Many Choices and Future Directions,” Cancer and Metastasis Reviews 41, no. 1 (2022): 193-209.

[386] J. Yoon and D. Y. Oh, “HER2-targeted Therapies Beyond Breast Cancer — an Update,” Nature reviews Clinical oncology 21, no. 9 (2024): 675-700.

[387] M. F. Mercogliano, S. Bruni, F. L. Mauro, and R. Schillaci, “Emerging Targeted Therapies for HER2-Positive Breast Cancer,” Cancers 15, no. 7 (2023): 1987.

[388] W. Geng, H. Thomas, Z. Chen, et al., “Mechanisms of Acquired Resistance to HER2-Positive Breast Cancer Therapies Induced by HER3: A Comprehensive Review,” European Journal of Pharmacology 977 (2024): 176725.

[389] V. Kardile, A. Kulkarni, B. Nadar, and T. Saldanha, “Monoclonal Antibodies in Oncology: A Decade of Novel Options,” Cell Biochemistry and Biophysics 81, no. 3 (2023): 395-408.

[390] J. Z. Drago, E. Ferraro, N. Abuhadra, and S. Modi, “Beyond HER2: Targeting the ErbB Receptor family in Breast Cancer,” Cancer Treatment Reviews 109 (2022): 102436.

[391] J. Veeraraghavan, C. De Angelis, C. Gutierrez, et al., “HER2-Positive Breast Cancer Treatment and Resistance,” Advances in Experimental Medicine and Biology 1464 (2025): 495-525.

[392] H. Maadi and Z. Wang, “A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells,” Cells 11, no. 24 (2022): 4093.

[393] M. Chaurasia, R. Singh, S. Sur, and S. J. S. Flora, “A Review of FDA Approved Drugs and Their Formulations for the Treatment of Breast Cancer,” Frontiers in pharmacology 14 (2023): 1184472.

[394] V. L. Cruz, V. Souza-Egipsy, M. Gion, et al., “Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †,” International Journal of Molecular Sciences 24, no. 15 (2023): 12031.

[395] J. Systematic Review, A. M. Cimpean, P. Maroni, E. Triantafyllidi, and J. K. Triantafillidis, “Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer,” Biomed 10, no. 8 (2022): 2045.

[396] E. Rubin, K. S. Shan, S. Dalal, et al., “Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various Cancers,” International Journal of Molecular Sciences 25, no. 2 (2024): 1064.

[397] L. C. Tsao, E. J. Crosby, T. N. Trotter, et al., “Trastuzumab/pertuzumab Combination Therapy Stimulates Antitumor Responses Through Complement-Dependent Cytotoxicity and Phagocytosis,” JCI Insight 7, no. 6 (2022): e155636.

[398] A. Musolino, W. J. Gradishar, H. S. Rugo, et al., “Role of Fcγ Receptors in HER2-targeted Breast Cancer Therapy,” Journal for ImmunoTherapy of Cancer 10, no. 1 (2022): e003171.

[399] X. Wu, S. Huang, W. He, and M. Song, “Emerging Insights Into Mechanisms of Trastuzumab Resistance in HER2-positive Cancers,” International Immunopharmacology 122 (2023): 110602.

[400] D. Ottewell, C. Theillet, S. Vivekanandhan, and K. L. Knutson, “Resistance to Trastuzumab,” Cancers 14, no. 20 (2022): 5115.

[401] D. Slamon, W. Eiermann, N. Robert, et al., “Adjuvant Trastuzumab in HER2-Positive Breast Cancer,” New England Journal of Medicine 365, no. 14 (2011): 1273-1283.

[402] D. Slamon, W. Eiermann, N. Robert, et al., “Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer,” Cancer Research 76, no. 4_Supplement (2016): S5-S14.

[403] E. A. Perez, E. H. Romond, V. J. Suman, et al., “Trastuzumab plus Adjuvant Chemotherapy for human Epidermal Growth Factor Receptor 2 - Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831,” Journal of Clinical Oncology 32, no. 33 (2014): 3744-3752.

[404] N. Dempsey, A. Rosenthal, N. Dabas, Y. Kropotova, M. Lippman, and N. H. Bishopric, “Trastuzumab-induced Cardiotoxicity: A Review of Clinical Risk Factors, Pharmacologic Prevention, and Cardiotoxicity of Other HER2-directed Therapies,” Breast Cancer Research and Treatment 188, no. 1 (2021): 21-36.

[405] N. I. Bouwer, T. G. Steenbruggen, H. N. Rier, et al., “The Effect of Trastuzumab on Cardiac Function in Patients With HER2-positive Metastatic Breast Cancer and Reduced Baseline Left Ventricular Ejection Fraction,” International Journal of Cancer 151, no. 4 (2022): 616-622.

[406] M. Jagosky and A. R. Tan, “Combination of Pertuzumab and Trastuzumab in the Treatment of her2-positive Early Breast Cancer: A Review of the Emerging Clinical Data,” Breast Cancer: Targets and Therapy 13 (2021): 393-407.

[407] A. Matusz-Fisher and A. R. Tan, “Combination of HER2-targeted Agents With Immune Checkpoint Inhibitors in the Treatment of HER2-positive Breast Cancer,” Expert Opinion on Biological Therapy 22, no. 3 (2022): 385-395.

[408] R. Sharma, M. Kumbhakar, and A. Mukherjee, “Toward Understanding the Binding Synergy of Trastuzumab and Pertuzumab to Human Epidermal Growth Factor Receptor 2,” Molecular Pharmaceutics 18, no. 12 (2021): 4553-4563.

[409] X. Wu, H. Yang, X. Yu, and J. J. Qin, “Drug-resistant HER2-positive Breast Cancer: Molecular Mechanisms and Overcoming Strategies,” Frontiers in pharmacology 13 (2022): 1012552.

[410] P. Mand, S. G. Rivero, M. M. Rizzo, M. Pinkasz, and E. M. Levy, “Targeting ADCC: A Different Approach to HER2 Breast Cancer in the Immunotherapy Era,” Breast (Edinburgh, Scotland) 60 (2021): 15-25. Published online 2021.

[411] X. Liu, Y. Fang, Y. Li, Y. Li, L. Qi, and X. Wang, “Pertuzumab Combined With Trastuzumab Compared to Trastuzumab in the Treatment of HER2-positive Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials,” Frontiers in oncology 12 (2022): 894861.

[412] M. Tapia, C. Hernando, M. T. Martínez, et al., “Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients With Resistance to Classical Anti-HER Therapies,” Cancers 15, no. 18 (2023): 4522.

[413] I. Ventura, N. P. Salcedo, M. Pérez-Bermejo, et al., “Pertuzumab in Combination With Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review,” International Journal of Molecular Sciences 26, no. 5 (2025): 1908.

[414] K. Debbi, N. Grellier, G. Loganadane, et al., “Interaction Between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence,” Cancers 15, no. 8 (2023): 2278.

[415] A. Beddok, P. Cottu, A. Fourquet, and Y. Kirova, “Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management,” Cancers 13, no. 24 (2021): 6358.

[416] S. M. Swain, D. Miles, S. B. Kim, et al., “Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-of-study Results From a Double-blind, Randomised, Placebo-controlled, Phase 3 Study,” The Lancet Oncology 21, no. 4 (2020): 519-530.

[417] A. R. M. Avelino, S. Pulipati, K. Jamouss, and P. V. Bhardwaj, “Updates in Treatment of HER2-positive Metastatic Breast Cancer,” Current Treatment Options in Oncology 25, no. 12 (2024): 1471-1481.

[418] M. Piccart, M. Procter, D. Fumagalli, et al., “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up,” Journal of Clinical Oncology 39, no. 13 (2021): 1448-1457.

[419] X. Li, X. Zhang, S. Yin, and J. Nie, “Challenges and Prospects in HER2-positive Breast Cancer-targeted Therapy,” Critical Reviews in Oncology/Hematology 207 (2025): 104624.

[420] L. Gianni, T. Pienkowski, Y. H. Im, et al., “Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-label, Phase 2 Trial,” The Lancet Oncology 13, no. 1 (2012): 25-32.

[421] L. Gianni, T. Pienkowski, Y. H. Im, et al., “5-year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients With Locally Advanced, Inflammatory, or Early-stage HER2-positive Breast Cancer (NeoSphere): A Multicentre, Open-label, Phase 2 Randomised Trial,” The Lancet Oncology 17, no. 6 (2016): 791-800.

[422] A. Van Der Voort, M. S. Van Ramshorst, E. D. Van Werkhoven, et al., “Three-Year Follow-up of Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients with ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial,” JAMA oncology 7, no. 7 (2021): 978-984.

[423] B. Demir Cetinkaya and C. Biray Avci, “Molecular Perspective on Targeted Therapy in Breast Cancer: A Review of Current Status,” Medical Oncology 39, no. 10 (2022): 1-12.

[424] J. Zekri, H. Rasool, S. A. J. Rizvi, et al., “Cardiac Function in Women Receiving Dual Anti-Her2 Antibodies (trastuzumab and pertuzumab) Combined With Chemotherapy for Breast Cancer,” Women's Heal 19 (2023): 17455057231166837.

[425] S. P. Zou, H. Y. Yang, M. L. Ouyang, Q. Cheng, X. Shi, and M. H. Sun, “A Disproportionality Analysis of Adverse Events Associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS),” BMC Pharmacology and Toxicology 24, no. 1 (2023): 1-11.

[426] C. Jackson, L. Finikarides, and A. L. J. Freeman, “The Adverse Effects of Trastuzumab-containing Regimes as a Therapy in Breast Cancer: A Piggy-back Systematic Review and Meta-analysis,” PLoS ONE 17, no. 12 (2022): e0275321.

[427] M. Tafani and M. M. Alasmari, “A Review of Margetuximab-Based Therapies in Patients With HER2-Positive Metastatic Breast Cancer,” Cancers 15, no. 1 (2022): 38.

[428] M. Royce, C. L. Osgood, A. K. Amatya, et al., “FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer,” Clinical Cancer Research 28, no. 8 (2022): 1487-1492.

[429] A. Markham, “Margetuximab: First Approval,” Drugs 81, no. 5 (2021): 599-604.

[430] Y. Zhou, X. Wang, and Y. Chen, “Margetuximab: An Active Alternative for Later-line Therapy in Patients With HER2-positive Advanced Breast Cancer,” MedComm 4, no. 4 (2023): e322.

[431] H. S. Rugo, S. A. Im, F. Cardoso, et al., “Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial,” JAMA oncology 7, no. 4 (2021): 573-584.

[432] I. Schlam, R. Nunes, and F. Lynce, “Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer,” OncoTargets and Therapy 15 (2022): 471-478.

[433] Q. Zhang, Q. Ouyang, W. Li, et al., “Efficacy and Safety of margetuximab plus Chemotherapy vs. trastuzumab plus Chemotherapy in Chinese Patients With Pretreated HER2-positive Advanced Metastatic Breast Cancer: Results From a Randomized, Open-label, Multicenter, Phase II Bridging Study,” Translational Breast Cancer Research 3 (2022): 31-31.

[434] H. S. Rugo, S. A. Im, F. Cardoso, et al., “Margetuximab versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial,” Journal of Clinical Oncology 41, no. 2 (2023): 198-205.

[435] A. T. Jacobs, D. Martinez Castaneda-Cruz, M. M. Rose, and L. Connelly, “Targeted Therapy for Breast Cancer: An Overview of Drug Classes and Outcomes,” Biochemical Pharmacology 204 (2022): 115209.

[436] S. Pernas and S. M. Tolaney, “Clinical Trial Data and Emerging Strategies: HER2-positive Breast Cancer,” Breast Cancer Research and Treatment 193, no. 2 (2022): 281-291.

[437] I. Essadi, Z. Benbrahim, M. Kaakoua, T. Reverdy, P. Corbaux, and G. Freyer, “HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments,” Cancers 15, no. 6 (2023): 1738.

[438] S. Shyam Sunder, U. C. Sharma, and S. Pokharel, “Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 1-27.

[439] Y. Yang, S. Li, Y. Wang, Y. Zhao, and Q. Li, “Protein Tyrosine Kinase Inhibitor Resistance in Malignant Tumors: Molecular Mechanisms and Future Perspective,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 1-36.

[440] D. Patra, K. Bhavya, P. Ramprasad, M. Kalia, and D. Pal, “Anti-cancer Drug Molecules Targeting Cancer Cell Cycle and Proliferation,” Advances in Protein Chemistry and Structural Biology 135 (2023): 343-395.

[441] V. Sankarapandian, R. L. Rajendran, C. O. Miruka, et al., “A Review on Tyrosine Kinase Inhibitors for Targeted Breast Cancer Therapy,” Pathology - Research and Practice 263 (2024): 155607.

[442] T. Fehm, V. Mueller, M. Banys-Paluchowski, et al., “Efficacy of Lapatinib in Patients With HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial,” Clinical Chemistry 70, no. 1 (2024): 307-318.

[443] S. Arora, P. Narayan, C. L. Osgood, et al., “U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review,” Clinical Cancer Research 28, no. 6 (2022): 1072-1086.

[444] A. Sahu, S. Verma, M. Varma, and M. K. Yadav, “Impact of ErbB Receptors and Anticancer Drugs Against Breast Cancer: A Review,” Current Pharmaceutical Biotechnology 23, no. 6 (2021): 787-802.

[445] P. J. Kaboli, S. Imani, M. Jomhori, and K. H. Ling, “Chemoresistance in Breast Cancer: PI3K/Akt Pathway Inhibitors vs the Current Chemotherapy,” American Journal of Cancer Research 11, no. 10 (2021): 5155, Accessed March 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8569340/.

[446] V. Angelis and A. F. C. Okines, “Systemic Therapies for HER2-Positive Advanced Breast Cancer,” Cancers 16, no. 1 (2023): 23.

[447] A. Ferrando-díez, E. Felip, A. Pous, M. B. Sirven, and M. Margelí, “Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer,” Cancers 14, no. 14 (2022): 3305.

[448] L. Sánchez-Lorenzo, A. Bachiller, C. Gea, and J. Espinós, “Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer,” Seminars in Oncology Nursing 40, no. 1 (2024): 151554.

[449] K. A. Gelmon, F. M. Boyle, B. Kaufman, et al., “Lapatinib or trastuzumab plus Taxane Therapy for human Epidermal Growth Factor Receptor 2-positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31,” Journal of Clinical Oncology 33, no. 14 (2015): 1574-1583.

[450] S. R. D. Johnston, R. Hegg, S. A. Im, et al., “Phase III, Randomized Study of Dual human Epidermal Growth Factor Receptor 2 (HER2) Blockade With lapatinib plus trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-positive, Hormone Receptor-positive Metastatic Breast Cancer: ALTERNATIVE,” Journal of Clinical Oncology 36, no. 8 (2018): 741-748.

[451] Y. Yuan, X. Liu, Y. Cai, and W. Li, “Lapatinib and lapatinib plus Trastuzumab Therapy versus Trastuzumab Therapy for HER2 Positive Breast Cancer Patients: An Updated Systematic Review and Meta-analysis,” Systematic Reviews 11, no. 1 (2022): 1-30.

[452] M. Kaleem, M. H. Dalhat, L. Azmi, et al., “An Insight Into Molecular Targets of Breast Cancer Brain Metastasis,” International Journal of Molecular Sciences 23, no. 19 (2022): 11687.

[453] J. Blanter, E. Baldwin, R. Patel, T. Sheng, and A. Tiersten, “Patterns in Use and Tolerance of Adjuvant Neratinib in Patients With Hormone Receptor (HR)-positive, HER2-positive Early-stage Breast Cancer,” Breast Cancer Research and Treatment 208, no. 2 (2024): 461-466.

[454] M. Arshad, A. Azad, P. Y. K. Chan, et al., “Neratinib Could be Effective as Monotherapy or in Combination With Trastuzumab in HER2-low Breast Cancer Cells and Organoid Models,” British Journal of Cancer 130, no. 12 (2024): 1990-2002.

[455] L. Guo, W. Shao, C. Zhou, et al., “Neratinib for HER2-positive Breast Cancer With an Overlooked Option,” Molecular Medicine 29, no. 1 (2023): 1-23.

[456] M. Martin, F. A. Holmes, B. Ejlertsen, et al., “Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 18, no. 12 (2017): 1688-1700.

[457] C. Saura, M. Oliveira, Y. H. Feng, et al., “Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-directed Regimens: Phase III NALA Trial,” Journal of Clinical Oncology 38, no. 27 (2020): 3138-3149.

[458] R. A. Freedman, H. M. Heiling, T. Li, et al., “Neratinib and ado-trastuzumab emtansine for Pretreated and Untreated human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022,” Annals of Oncology 35, no. 11 (2024): 993-1002.

[459] R. Caputo, G. Buono, and V. Di Lauro, “Neratinib as Adjuvant Therapy in Patients With HER2 Positive Breast Cancer: Expert Opinion,” Future Oncology 19, no. 24 (2023): 1695-1708.

[460] Z. Sirhan, A. Thyagarajan, and R. P. Sahu, “The Efficacy of Tucatinib-based Therapeutic Approaches for HER2-positive Breast Cancer,” Military Medical Research 9, no. 1 (2022): 1-9.

[461] D. Zhang, A. Taylor, J. J. Zhao, C. J. Endres, and A. Topletz-Erickson, “Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients With Breast Cancer or Colorectal Cancer,” Clinical Pharmacokinetics 63, no. 10 (2024): 1477-1487.

[462] M. Shah, S. Wedam, J. Cheng, et al., “FDA Approval Summary: Tucatinib for the Treatment of Patients With Advanced or Metastatic HER2-positive Breast Cancer,” Clinical Cancer Research 27, no. 5 (2021): 1220-1226.

[463] L. Ulrich and A. F. C. Okines, “Treating Advanced Unresectable or Metastatic HER2-positive Breast Cancer: A Spotlight on tucatinib,” Breast Cancer: Targets and Therapy 13 (2021): 361-381.

[464] C. L. Fernandes, D. J. Silva, and A. Mesquita, “Novel HER-2 Targeted Therapies in Breast Cancer,” Cancers 16, no. 1 (2023): 87.

[465] I. Bansal, A. K. Pandey, and M. Ruwali, “Small-molecule Inhibitors of Kinases in Breast Cancer Therapy: Recent Advances, Opportunities, and Challenges,” Frontiers in pharmacology 14 (2023): 1244597.

[466] R. K. Murthy, S. Loi, A. Okines, et al., “Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer,” New England Journal of Medicine 382, no. 7 (2020): 597-609.

[467] G. Curigliano, V. Mueller, V. Borges, et al., “Tucatinib versus Placebo Added to trastuzumab and Capecitabine for Patients With Pretreated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis,” Annals of Oncology 33, no. 3 (2022): 321-329.

[468] C. Criscitiello, C. Corti, M. De Laurentiis, et al., “Tucatinib's Journey From Clinical Development to Clinical Practice: New Horizons for HER2-positive Metastatic Disease and Promising Prospects for Brain Metastatic Spread,” Cancer Treatment Reviews 120 (2023): 102618.

[469] X. Qi, Q. Shi, J. Xuhong, Y. Zhang, and J. Jiang, “Pyrotinib-based Therapeutic Approaches for HER2-positive Breast Cancer: The Time Is Now,” Breast Cancer Research 25, no. 1 (2023): 1-11.

[470] Z. Wu, J. Wang, F. You, X. Li, and C. Xiao, “The Role of Irreversible Pan-HER Tyrosine Kinase Inhibitors in the Treatment of HER2-Positive Metastatic Breast Cancer,” Frontiers in pharmacology 14 (2023): 1142087.

[471] X. F. Xie, Q. Y. Zhang, J. Y. Huang, et al., “Pyrotinib Combined With trastuzumab and Chemotherapy for the Treatment of human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer: A Single-arm Exploratory Phase II Trial,” Breast Cancer Research and Treatment 197, no. 1 (2023): 93-101.

[472] L. Dai, T. Gao, R. Guo, et al., “Efficacy and Safety of Pyrotinib-based Regimens in HER2 Positive Metastatic Breast Cancer: A Retrospective Real-world Data Study,” Neoplasia 56 (2024): 101029.

[473] C. Wang, S. Deng, J. Chen, et al., “The Synergistic Effects of Pyrotinib Combined with Adriamycin on HER2-Positive Breast Cancer,” Frontiers in oncology 11 (2021): 616443.

[474] B. Xu, M. Yan, F. Ma, et al., “Pyrotinib plus Capecitabine versus Lapatinib plus Capecitabine for the Treatment of HER2-positive Metastatic Breast Cancer (PHOEBE): A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial,” The Lancet Oncology 22, no. 3 (2021): 351-360.

[475] F. Ma, M. Yan, W. Li, et al., “Pyrotinib versus Placebo in Combination With trastuzumab and Docetaxel as First Line Treatment in Patients With HER2 Positive Metastatic Breast Cancer (PHILA): Randomised, Double Blind, Multicentre, Phase 3 Trial,” Bmj 383 (2023): e076065.

[476] W. Yin, Y. Wang, Z. Wu, et al., “Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study,” Clinical Cancer Research 28, no. 17 (2022): 3677-3685.

[477] X. Zhong, P. He, J. Chen, et al., “Neoadjuvant Pyrotinib plus Trastuzumab and Nab-paclitaxel for HER2-positive Early or Locally Advanced Breast Cancer: An Exploratory Phase II Trial,” Gland Surgery 11, no. 1 (2022): 216-225.

[478] D. Huang and W. L. Kraus, “The Expanding Universe of PARP1-mediated Molecular and Therapeutic Mechanisms,” Molecular Cell 82, no. 12 (2022): 2315-2334.

[479] L. Yu, Z. W. Yan, Y. de Wang, et al., “Recent Advances in Structural Types and Medicinal Chemistry of PARP-1 Inhibitors,” Medicinal Chemistry Research 31, no. 8 (2022): 1265-1276.

[480] S. Li, L. Wang, Y. Wang, C. Zhang, Z. Hong, and Z. Han, “The Synthetic Lethality of Targeting Cell Cycle Checkpoints and PARPs in Cancer Treatment,” Journal of hematology & oncology 15, no. 1 (2022): 1-32.

[481] Y. Han, V. Rovella, A. Smirnov, et al., “A BRCA2 Germline Mutation and High Expression of Immune Checkpoints in a TNBC Patient,” Cell Death Discovery 9, no. 1 (2023): 1-9.

[482] C. Zong, T. Zhu, J. He, R. Huang, R. Jia, and J. Shen, “PARP Mediated DNA Damage Response, Genomic Stability and Immune Responses,” International Journal of Cancer 150, no. 11 (2022): 1745-1759.

[483] A. Jain, A. Barge, and C. N. Parris, “Combination Strategies With PARP Inhibitors in BRCA-mutated Triple-negative Breast Cancer: Overcoming Resistance Mechanisms,” Oncogene 44, no. 4 (2024): 193-207.

[484] S. Morganti, A. Marra, C. De Angelis, et al., “PARP Inhibitors for Breast Cancer Treatment: A Review,” JAMA oncology 10, no. 5 (2024): 658-670.

[485] L. Luo and K. Keyomarsi, “PARP Inhibitors as Single Agents and in Combination Therapy: The Most Promising Treatment Strategies in Clinical Trials for BRCA-mutant Ovarian and Triple-negative Breast Cancers,” Expert Opinion on Investigational Drugs 31, no. 6 (2022): 607-631.

[486] T. A. Yap and R. L. Coleman, “The Principles and Practice of PARP Inhibitor Therapy,” Cancer J (United States) 27, no. 6 (2021): 430-431.

[487] R. A. Dent, G. J. Lindeman, M. Clemons, et al., “Phase I Trial of the Oral PARP Inhibitor olaparib in Combination With paclitaxel for First- or Second-line Treatment of Patients With Metastatic Triple-negative Breast Cancer,” Breast Cancer Research 15, no. 5 (2013): R88.

[488] H. P. Eikesdal, S. Yndestad, A. Elzawahry, et al., “Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer,” Annals of Oncology 32, no. 2 (2021): 240-249.

[489] A. N. J. Tutt, J. E. Garber, B. Kaufman, et al., “Adjuvant Olaparib for Patients With BRCA1 - or BRCA2 -Mutated Breast Cancer,” New England Journal of Medicine 384, no. 25 (2021): 2394-2405.

[490] J. M. Lee, J. L. Hays, V. L. Chiou, et al., “Phase I/Ib Study of Olaparib and Carboplatin in Women With Triple Negative Breast Cancer,” Oncotarget 8, no. 45 (2017): 79175-79187.

[491] F. Batalini, N. Xiong, N. Tayob, et al., “Phase 1b Clinical Trial With Alpelisib plus Olaparib for Patients With Advanced Triple-Negative Breast Cancer,” Clinical Cancer Research 28, no. 8 (2022): 1493-1499.

[492] Y. Zhou, S. Zhao, T. Wu, and H. Zhang, “Comparison of Adverse Reactions Caused by Olaparib for Different Indications,” Frontiers in pharmacology 13 (2022): 968163.

[493] W. Jin, Q. Yang, Z. Zhang, and J. Li, “Olaparib-associated Toxicity in Cancer Patients: A Systematic Review and Meta-analysis,” European Journal of Clinical Pharmacology 81, no. 1 (2024): 65-81.

[494] Y. Zeng, O. Arisa, C. J. Peer, A. Fojo, and W. D. Figg, “PARP Inhibitors: A Review of the Pharmacology, Pharmacokinetics, and Pharmacogenetics,” Seminars in Oncology 51, no. 1-2 (2024): 19-24.

[495] E. L. Beas-Lozano, H. C. Verduzco-Aguirre, R. Gonzalez-Salazar, and Y. Chavarri-Guerra, “Real-world Data in Patients With BRCA Mutated Breast Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors,” Ecancermedicalscience 17 (2023): 1633.

[496] S. D. Fontaine, G. W. Ashley, P. J. Houghton, et al., “A Very Long-acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-deficient Tumor Models,” Cancer Research 81, no. 4 (2021): 1076-1086.

[497] S. A. Piha-Paul, C. Tseng, C. H. Leung, et al., “Phase II Study of Talazoparib in Advanced Cancers With BRCA1/2, DNA Repair, and PTEN Alterations,” Npj Precis Oncology 8, no. 1 (2024): 1-14.

[498] E. A. Hobbs, J. K. Litton, and T. A. Yap, “Development of the PARP Inhibitor Talazoparib for the Treatment of Advanced BRCA1 and BRCA2 Mutated Breast Cancer,” Expert Opinion on Pharmacotherapy 22, no. 14 (2021): 1825-1837.

[499] J. K. Litton, H. S. Rugo, J. Ettl, et al., “Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation,” New England Journal of Medicine 379, no. 8 (2018): 753-763.

[500] J. K. Litton, J. T. Beck, J. M. Jones, et al., “Neoadjuvant Talazoparib in Patients with Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study,” The Oncologist 28, no. 10 (2023): 845.

[501] J. Sohn, M. H. Kim, G. M. Kim, et al., “A Randomized Phase II Clinical Trial of talazoparib Maintenance Therapy in Patients With Triple-negative Breast Cancer Who Showed Platinum-sensitivity on First- or Second-line Platinum-based Chemotherapy: KCSG BR21-10,” Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1132-TPS1132.

[502] D. Sandhu, A. A. Antolin, A. R. Cox, and A. M. Jones, “Identification of Different Side Effects Between PARP Inhibitors and Their Polypharmacological Multi-target Rationale,” British Journal of Clinical Pharmacology 88, no. 2 (2022): 742-752.

[503] X. Tian, L. Chen, D. Gai, S. He, X. Jiang, and N. Zhang, “Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS,” Frontiers in pharmacology 13 (2022): 851246.

[504] M. Tang, P. Liu, L. Du, Y. Li, J. Chen, and Y. Li, “Detection and Analysis of the Safety Profile of talazoparib Based on FAERS Database,” Expert Opinion on Drug Safety 24, no. 5 (2025): 577-584. Published online August 17, 2024.

[505] Y. Li, Z. Zhan, X. Yin, S. Fu, and X. Deng, “Targeted Therapeutic Strategies for Triple-Negative Breast Cancer,” Frontiers in oncology 11 (2021): 731535.

[506] E. T. Rodler, B. F. Kurland, M. Griffin, et al., “Phase I Study of Veliparib (ABT-888) Combined With Cisplatin and Vinorelbine in Advanced Triple-negative Breast Cancer and/or BRCA Mutation-associated Breast Cancer,” Clinical Cancer Research 22, no. 12 (2016): 2855-2864.

[507] H. S. Rugo, O. I. Olopade, A. DeMichele, et al., “Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer,” New England Journal of Medicine 375, no. 1 (2016): 23-34.

[508] Y. Li, H. Zhang, Y. Merkher, et al., “Recent Advances in Therapeutic Strategies for Triple-negative Breast Cancer,” Journal of hematology & oncology 15, no. 1 (2022): 1-30.

[509] S. Loibl, J. O'Shaughnessy, and M. Untch, “Addition of the PARP Inhibitor Veliparib plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial,” The Lancet Oncology 19, no. 4 (2018): 497-509.

[510] M. K. Malhotra, S. Pahuja, B. F. Kiesel, et al., “A Phase 1 Study of Veliparib (ABT-888) plus Weekly Carboplatin and Paclitaxel in Advanced Solid Malignancies, With an Expansion Cohort in Triple Negative Breast Cancer (TNBC) (ETCTN 8620),” Breast Cancer Research and Treatment 198, no. 3 (2023): 487-498.

[511] D. D. Singh, A. Parveen, and D. K. Yadav, “Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance,” Biomed 9, no. 11 (2021): 1512.

[512] S. Vinayak, S. M. Tolaney, L. Schwartzberg, et al., “Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer,” JAMA oncology 5, no. 8 (2019): 1132-1140.

[513] J. C. Keenan, S. A. Dunn, M. E. Collins, et al., “A Phase I Study of Adjuvant Niraparib Administered Concurrently With Postoperative Radiation Therapy in Patients With Localized Triple Negative Breast Cancer,” International Journal of Radiation Oncology 114, no. 3 (2022): S44.

[514] L. A. Orofiamma, D. Vural, and C. N. Antonescu, “Control of Cell Metabolism by the Epidermal Growth Factor Receptor,” Biochimica et Biophysica Acta - Molecular Cell Research 1869, no. 12 (2022): 119359.

[515] M. L. Uribe, I. Marrocco, and Y. Yarden, “EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance,” Cancers 13, no. 11 (2021): 2748.

[516] M. Ramírez Moreno and N. A. Bulgakova, “The Cross-Talk between EGFR and E-Cadherin,” Frontiers in Cell and Developmental Biology 9 (2022): 828673.

[517] L. Yin, J. J. Duan, X. W. Bian, and S. C. Yu, “Triple-negative Breast Cancer Molecular Subtyping and Treatment Progress,” Breast Cancer Research 22, no. 1 (2020): 1-13.

[518] J. Baselga, P. Gómez, R. Greil, et al., “Randomized Phase II Study of the Anti-epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin versus Cisplatin Alone in Patients With Metastatic Triple-negative Breast Cancer,” Journal of Clinical Oncology 31, no. 20 (2013): 2586-2592.

[519] J. M. Nabholtz, M. A. Mouret-Reynier, I. Van-Praagh, et al., “Cetuximab in Combination With docetaxel (T) in Patients With Operable, Triple-negative Breast Cancer (TNBC): Preliminary Results of a Multicentre Neoadjuvant Pilot Phase II Study,” Journal of Clinical Oncology 31, no. 15_suppl (2013): 1057-1057.

[520] O. Trédan, M. Campone, J. Jassem, et al., “Ixabepilone Alone or with Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer,” Clinical Breast Cancer 15, no. 1 (2015): 8-15.

[521] W. S. Liao, Y. Ho, Y. W. Lin, et al., “Targeting EGFR of Triple-negative Breast Cancer Enhances the Therapeutic Efficacy of paclitaxel- and cetuximab-conjugated Nanodiamond Nanocomposite,” Acta Biomaterialia 86 (2019): 395-405.

[522] C. Mamot, A. Wicki, U. Hasler-Strub, et al., “A Multicenter Phase II Trial of Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative Breast Cancer,” Scientific Reports 13, no. 1 (2023): 3705.

[523] A. Canonici, A. L. Browne, M. F. K. Ibrahim, et al., “Combined Targeting EGFR and SRC as a Potential Novel Therapeutic Approach for the Treatment of Triple Negative Breast Cancer,” Therapeutic Advances in Medical Oncology 12 (2020): 1758835919897546.

[524] C. Yam, M. Patel, H. A. Hill, et al., “Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study,” Cancer Research Communications 4, no. 10 (2024): 2823-2834.

[525] Z. L. Liu, H. H. Chen, L. L. Zheng, L. P. Sun, and L. Shi, “Angiogenic Signaling Pathways and Anti-angiogenic Therapy for Cancer,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 1-39.

[526] A. Ahmad and M. I. Nawaz, “Molecular Mechanism of VEGF and Its Role in Pathological Angiogenesis,” Journal of Cellular Biochemistry 123, no. 12 (2022): 1938-1965.

[527] A. Abdel-Wahab, “Angiogenesis Inhibitors in the Treatment of Cancer,” Handb Cancer Immunol (2023): 1-33, https://doi.org/10.1007/978-3-030-80962-1_274-1. Published online.

[528] M. J. Ansari, D. Bokov, A. Markov, et al., “Cancer Combination Therapies by Angiogenesis Inhibitors; a Comprehensive Review,” Cell Communication and Signaling 20, no. 1 (2022): 1-23.

[529] N. M. Ayoub, S. K. Jaradat, K. M. Al-Shami, and A. E. Alkhalifa, “Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches,” Frontiers in pharmacology 13 (2022): 838133.

[530] C. Thomssen, J. Y. Pierga, K. I. Pritchard, et al., “First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study,” Oncology 82, no. 4 (2012): 218-227.

[531] A. Brufsky, V. Valero, B. Tiangco, et al., “Second-line Bevacizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Subgroup Analysis of the RIBBON-2 Trial,” Breast Cancer Research and Treatment 133, no. 3 (2012): 1067-1075.

[532] B. Gerber, S. Loibl, H. Eidtmann, et al., “Neoadjuvant bevacizumab and Anthracycline-taxane-based Chemotherapy in 678 Triple-negative Primary Breast Cancers; Results From the geparquinto Study (GBG 44),” Annals of Oncology 24, no. 12 (2013): 2978-2984.

[533] H. R. Kim, K. H. Jung, S. A. Im, et al., “Multicentre Phase II Trial of Bevacizumab Combined With Docetaxel-carboplatin for the Neoadjuvant Treatment of Triple-negative Breast Cancer (KCSG BR-0905),” Annals of Oncology 24, no. 6 (2013): 1485-1490.

[534] W. M. Sikov, D. A. Berry, C. M. Perou, et al., “Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-week Paclitaxel Followed by Dose-dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-negative Breast Cancer: CALGB 40603 (Alliance),” Journal of Clinical Oncology 33, no. 1 (2015): 13-21.

[535] R. Bell, J. Brown, M. Parmar, et al., “Final Efficacy and Updated Safety Results of the Randomized Phase III BEATRICE Trial Evaluating Adjuvant Bevacizumab-containing Therapy in Triple-negative Early Breast Cancer,” Annals of Oncology 28, no. 4 (2017): 754-760.

[536] S. Gupta, G. K. Babu, R. T. Chacko, et al., “An Open Label, Single Arm, Prospective Phase II Study to Evaluate the Efficacy and Safety of bevacizumab With Gemcitabine and Carboplatin as First-line Treatment for Metastatic Triple Negative Breast Cancer Patients,” Journal of Clinical Oncology 36, no. 15_suppl (2018): 1098-1098.

[537] M. Gion, P. Cortez-Castedo, I. Blancas, et al., “Abstract PS16-02: Efficacy and Safety of First-line Atezolizumab + Bevacizumab + Paclitaxel in Patients With Advanced Triple-negative Breast Cancer: The ATRACTIB Phase 2 Trial,” Cancer Research 84, no. 9_Supplement (2024): PS16-PS102.

[538] X. Hu, J. Zhang, B. Xu, et al., “Multicenter Phase II Study of apatinib, a Novel VEGFR Inhibitor in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer,” International Journal of Cancer 135, no. 8 (2014): 1961-1969.

[539] J. Liu, Q. Liu, Y. Li, et al., “Efficacy and Safety of camrelizumab Combined With Apatinib in Advanced Triple-Negative Breast Cancer: An Open-Label Phase II Trial,” Journal for ImmunoTherapy of Cancer 8, no. 1 (2020): 696.

[540] J. R. Diamond, S. G. Eckhardt, T. M. Pitts, et al., “A Phase II Clinical Trial of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 for Previously Treated, Advanced, or Metastatic Triple-Negative Breast Cancer,” Breast Cancer Research 20, no. 1 (2018): 1-10.

[541] L. Wang, Y. Fei, H. Qu, et al., “Five Years of Safety Profile of bevacizumab: An Analysis of Real-world Pharmacovigilance and Randomized Clinical Trials,” Journal of Pharmaceutical Health Care and Sciences 10, no. 1 (2024): 1-15.

[542] P. P. Patil, R. R. Rangaraju, W. Abbas, and S. Garg, “Real-World Experience in Toxicity With Bevacizumab in Indian Cancer Patients,” South Asian Journal of Cancer 10, no. 2 (2021): 131-134.

[543] F. P. de Oliveira, M. L. Nogueira, A. F. C. Galvão, R. B. Dias, and D. P. Bezerra, “Translational Drugs Targeting Cancer Stem Cells in Triple-negative Breast Cancer,” Molecular Therapy Oncology 33, no. 3 (2025): 201008.

[544] A. C. Garrido-Castro, C. Saura, R. Barroso-Sousa, et al., “Phase 2 Study of buparlisib (BKM120), a Pan-class I PI3K Inhibitor, in Patients With Metastatic Triple-negative Breast Cancer,” Breast Cancer Research 22, no. 1 (2020): 1-13.

[545] N. A. Bagegni, L. Nehring, J. Anderson, et al., “A Phase I/II Trial Evaluating the Safety and Efficacy of eribulin in Combination With copanlisib in Patients With Metastatic Triple-negative Breast Cancer (TNBC),” Journal of Clinical Oncology 40, no. 16_suppl (2022): TPS1128-TPS1128.

[546] P. Schmid, J. Abraham, S. Chan, et al., “Capivasertib plus paclitaxel versus Placebo plus paclitaxel as First-line Therapy for Metastatic Triple-negative Breast Cancer: The PAKT Trial,” Journal of Clinical Oncology 38, no. 5 (2020): 423-433.

[547] R. Dent, M. Oliveira, S. J. Isakoff, et al., “Final Results of the Double-blind Placebo-controlled Randomized Phase 2 LOTUS Trial of First-line ipatasertib plus paclitaxel for Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer,” Breast Cancer Research and Treatment 189, no. 2 (2021): 377-386.

[548] E. Lopez-Miranda, J. M. Pérez García, and M. Gion, “Ipatasertib (IPA) Combined With Non-taxane Chemotherapy (CT) for Patients (pts) With Previously Treated Advanced Triple-negative Breast Cancer (aTNBC): The PATHFINDER Phase IIa Trial,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 1098-1098.

[549] K. Anand, T. Patel, P. Niravath, et al., “Targeting mTOR and DNA Repair Pathways in Residual Triple Negative Breast Cancer Post Neoadjuvant Chemotherapy,” Scientific Reports 11, no. 1 (2021): 1-8.

[550] L. Fan, Z. H. Wang, L. X. Ma, et al., “Optimising First-line Subtyping-based Therapy in Triple-negative Breast Cancer (FUTURE-SUPER): A Multi-cohort, Randomised, Phase 2 Trial,” The Lancet Oncology 25, no. 2 (2024): 184-197.

[551] J. Rodon, G. Argilés, R. M. Connolly, et al., “Phase 1 Study of Single-agent WNT974, a First-in-class Porcupine Inhibitor, in Patients With Advanced Solid Tumours,” British Journal of Cancer 125, no. 1 (2021): 28-37.

[552] M. Radovich, J. P. Solzak, C. J. Wang, et al., “Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients With Metastatic Triple-Negative Breast Cancer,” Clinical Cancer Research 28, no. 15 (2022): 3235-3241.

[553] P. Peng, X. Qiang, G. Li, et al., “Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active against Triple-Negative Breast Cancer,” Molecular Cancer Therapeutics 22, no. 2 (2023): 205-214.

[554] E. Mrozek, R. Wesolowski, M. B. Lustberg, et al., “A Phase I Study of Neoadjuvant Chemotherapy (NCT) With the Gamma Secretase (GS) Inhibitor RO4929097 in Combination With paclitaxel (P) and Carboplatin (C) in Women With Triple-negative Breast Cancer (TNBC),” Journal of Clinical Oncology 31, no. 15_suppl (2013): 1043-1043.

[555] M. A. Locatelli, P. Aftimos, E. C. Dees, et al., “Phase I Study of the Gamma Secretase Inhibitor PF-03084014 in Combination With docetaxel in Patients With Advanced Triple-negative Breast Cancer,” Oncotarget 8, no. 2 (2016): 2320-2328.

[556] Z. Fu, S. Li, S. Han, C. Shi, and Y. Zhang, “Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 1-25.

[557] L. Guidi, G. Pellizzari, P. Tarantino, C. Valenza, and G. Curigliano, “Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges,” Cancers 15, no. 4 (2023): 1130.

[558] F. Riccardi, M. Dal Bo, P. Macor, and G. Toffoli, “A Comprehensive Overview on Antibody-drug Conjugates: From the Conceptualization to Cancer Therapy,” Frontiers in pharmacology 14 (2023): 1274088.

[559] R. Sheyi, B. G. de la Torre, and F. Albericio, “Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate,” pharmacy 14, no. 2 (2022): 396.

[560] L. Lu, Z. Niu, Z. Chao, C. Fu, K. Chen, and Y. Shi, “Exploring the Therapeutic Potential of ADC Combination for Triple-negative Breast Cancer,” Cellular and Molecular Life Sciences 80, no. 12 (2023): 1-14.

[561] H. E. Marei, C. Cenciarelli, and A. Hasan, “Potential of Antibody-drug Conjugates (ADCs) for Cancer Therapy,” Cancer cell international 22, no. 1 (2022): 1-12.

[562] E. Díaz-Rodríguez, L. Gandullo-Sánchez, A. Ocaña, and A. Pandiella, “Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs,” Cancers 14, no. 1 (2021): 154.

[563] P. Tarantino and S. M. Tolaney, “The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors,” Cancer Research 82, no. 20 (2022): 3659-3661.

[564] S. L. Graff, F. Yan, and Y. Abdou, “Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer,” Clinical Breast Cancer 23, no. 7 (2023): e380-e393.

[565] J. Yu, T. Fang, C. Yun, X. Liu, and X. Cai, “Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers,” Frontiers in Molecular Biosciences 9 (2022): 847835.

[566] A. C. Marques, P. C. da Costa, S. Velho, and M. H. Amaral, “Trastuzumab for Active Targeting in Cancer Therapy,” Handb Cancer Immunol (2024): 1-30, https://doi.org/10.1007/978-3-030-80962-1_396-1. Published online.

[567] M. Bohlmann, R. D. Hofheinz, S. Lorenzen, B. S. Zimmerman, and F. J. Esteva, “Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer,” Cancers 16, no. 4 (2024): 800.

[568] R. Khoury, K. Saleh, N. Khalife, et al., “Mechanisms of Resistance to Antibody-Drug Conjugates,” International Journal of Molecular Sciences 24, no. 11 (2023): 9674.

[569] V. Diéras, D. Miles, S. Verma, et al., “Trastuzumab Emtansine versus Capecitabine plus Lapatinib in Patients With Previously Treated HER2-positive Advanced Breast Cancer (EMILIA): A Descriptive Analysis of Final Overall Survival Results From a Randomised, Open-label, Phase 3 Trial,” The Lancet Oncology 18, no. 6 (2017): 732-742.

[570] I. E. Krop, S. B. Kim, A. G. Martin, et al., “Trastuzumab emtansine versus Treatment of Physician's Choice in Patients With Previously Treated HER2-positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results From a Randomised Open-label Phase 3 Trial,” The Lancet Oncology 18, no. 6 (2017): 743-754.

[571] E. A. Perez, C. Barrios, W. Eiermann, et al., “Trastuzumab Emtansine With or Without Pertuzumab versus Trastuzumab With taxane for human Epidermal Growth Factor Receptor 2-positive Advanced Breast Cancer: Final Results From MARIANNE,” Cancer 125, no. 22 (2019): 3974-3984.

[572] E. P. Mamounas, M. Untch, M. S. Mano, et al., “Adjuvant T-DM1 versus Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for HER2-positive Breast Cancer: Subgroup Analyses From KATHERINE,” Annals of Oncology 32, no. 8 (2021): 1005-1014.

[573] I. E. Krop, S. A. Im, C. Barrios, et al., “Trastuzumab Emtansine plus Pertuzumab versus Taxane plus Trastuzumab plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study,” Journal of Clinical Oncology 40, no. 5 (2022): 438-448.

[574] C. Molinelli, F. Parisi, M. G. Razeti, et al., “Trastuzumab emtansine (T-DM1) as Adjuvant Treatment of HER2-positive Early Breast Cancer: Safety and Efficacy,” Expert Review of Anticancer Therapy 21, no. 3 (2021): 241-250.

[575] K. Liu, Y. H. Li, X. Zhang, et al., “Incidence and Risk of Severe Adverse Events Associated With trastuzumab emtansine (T-DM1) in the Treatment of Breast Cancer: An up-to-date Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials,” Expert Review of Clinical Pharmacology 15, no. 11 (2022): 1343-1350.

[576] G. Antonarelli, C. Corti, P. Tarantino, et al., “Management of Patients With HER2-positive Metastatic Breast Cancer After Trastuzumab Deruxtecan Failure,” ESMO Open 8, no. 4 (2023): 101608.

[577] M. Martín, A. Pandiella, E. Vargas-Castrillón, et al., “Trastuzumab Deruxtecan in Breast Cancer,” Critical Reviews in Oncology/Hematology 198 (2024): 104355.

[578] M. R. Monteiro, N. C. C. Nunes, A. A. da Silva Junior, et al., “Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads,” Breast Cancer: Targets and Therapy 16 (2024): 51-70.

[579] C. Mark, J. S. Lee, X. Cui, and Y. Yuan, “Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions,” International Journal of Molecular Sciences 24, no. 18 (2023): 13726.

[580] I. M. Werter, S. Remmelzwaal, G. L. Burchell, et al., “Systemic Therapy for Patients With HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis,” Cancers (Basel) 14, no. 22 (2022): 5612.

[581] J. Yu, M. Li, X. Liu, et al., “Implementation of Antibody-drug Conjugates in HER2-positive Solid Cancers: Recent Advances and Future Directions,” Biomedicine & Pharmacotherapy 174 (2024): 116522.

[582] M. A. Subhan and V. P. Torchilin, “Advances in Targeted Therapy of Breast Cancer With Antibody-Drug Conjugate,” Pharmacy 15, no. 4 (2023): 1242.

[583] A. Q. Dean, S. Luo, J. D. Twomey, and B. Zhang, “Targeting Cancer With Antibody-drug Conjugates: Promises and Challenges,” MAbs 13, no. 1 (2021): 1951427.

[584] J. Cortés, S. B. Kim, W. P. Chung, et al., “Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer,” New England Journal of Medicine 386, no. 12 (2022): 1143-1154.

[585] E. Ciruelos, J. Á. García-Sáenz, J. Gavilá, M. Martín, C. A. Rodríguez, and Á. Rodríguez-Lescure, “Safety Profile of Trastuzumab deruxtecan in Advanced Breast Cancer: Expert Opinion on Adverse Event Management,” Clinical & translational oncology 26, no. 7 (2024): 1539-1548.

[586] F. Liu, G. Yin, S. Xue, F. U. L. Rehman, D. Liao, and Y. Pan, “Adverse Event Profile Differences Between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study,” Journal of Cancer 14, no. 17 (2023): 3275.

[587] Y. Jeon, U. Jo, J. Hong, G. Gong, and H. J. Lee, “Trophoblast Cell-surface Antigen 2 (TROP2) Expression in Triple-negative Breast Cancer,” BMC cancer 22, no. 1 (2022): 1-9.

[588] H. Izci, K. Punie, L. Waumans, et al., “Correlation of TROP-2 Expression With Clinical-pathological Characteristics and Outcome in Triple-negative Breast Cancer,” Scientific Reports 12, no. 1 (2022): 1-11.

[589] E. Sakach, R. Sacks, and K. Kalinsky, “Trop-2 as a Therapeutic Target in Breast Cancer,” Cancers 14, no. 23 (2022): 5936.

[590] M. Randall, R. Akers, and R. Rao, “A Review of Current and Future Antibody Drug Conjugates in Breast Cancer,” Current Treatment Options in Oncology 25, no. 12 (2024): 1506-1516.

[591] K. Kalinsky, J. R. Diamond, L. T. Vahdat, et al., “Sacituzumab govitecan in Previously Treated Hormone Receptor-positive/HER2-negative Metastatic Breast Cancer: Final Results From a Phase I/II, Single-arm, Basket Trial,” Annals of Oncology 31, no. 12 (2020): 1709-1718.

[592] H. S. Rugo, A. Bardia, S. M. Tolaney, et al., “TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2-metastatic Breast Cancer,” Future Oncology 16, no. 12 (2020): 705-712.

[593] H. S. Rugo, A. Bardia, F. Marmé, et al., “Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,” Journal of Clinical Oncology 40, no. 29 (2022): 3365-3376.

[594] H. S. Rugo, A. Bardia, F. Marmé, et al., “LBA76 Overall Survival (OS) Results From the Phase III TROPiCS-02 Study of sacituzumab govitecan (SG) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HR+/HER2- metastatic Breast Cancer (mBC),” Annals of Oncology 33 (2022): S1386.

[595] A. Bardia, I. A. Mayer, L. T. Vahdat, et al., “Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer,” New England Journal of Medicine 380, no. 8 (2019): 741-751.

[596] A. Bardia, S. A. Hurvitz, S. M. Tolaney, et al., “Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,” New England Journal of Medicine 384, no. 16 (2021): 1529-1541.

[597] L. Spring, S. M. Tolaney, N. V. Desai, et al., “Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-negative Breast Cancer: Results From the NeoSTAR Trial,” Journal of Clinical Oncology 40, no. 16_suppl (2022): 512-512.

[598] R. O. Abelman, L. Spring, A. Niemierko, et al., “Sequential Combination of Sacituzumab Govitecan and Talazoparib in Metastatic Triple Negative Breast Cancer (mTNBC): Results From a Phase II Study,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 1102-1102.

[599] Y. Wang, H. Zhang, C. Liu, et al., “Immune Checkpoint Modulators in Cancer Immunotherapy: Recent Advances and Emerging Concepts,” Journal of hematology & oncology 15, no. 1 (2022): 1-53.

[600] L. Han, T. Wu, Q. Zhang, A. Qi, and X. Zhou, “Immune Tolerance Regulation Is Critical to Immune Homeostasis,” Journal of Immunology Research 2025, no. 1 (2025): 5006201.

[601] S. Ali, M. Arshad, M. Summer, et al., “Recent Developments on Checkpoint Inhibitors, CAR T Cells, and Beyond for T Cell-based Immunotherapeutic Strategies Against Cancer,” Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners 31, no. 7 (2025): 1115-1144. Published online 2025.

[602] X. Sun, K. Liu, S. Lu, W. He, and Z. Du, “Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer,” Cancers 14, no. 21 (2022): 5456.

[603] M. Wu, Q. Huang, Y. Xie, et al., “Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade via Combination Therapy and PD-L1 Regulation,” Journal of hematology & oncology 15, no. 1 (2022): 1-58.

[604] C. Isaacs, R. Nanda, J. Chien, et al., “Abstract GS5-03: Evaluation of Anti-PD-1 Cemiplimab plus Anti-LAG-3 REGN3767 in Early-stage, High-risk HER2-negative Breast Cancer: Results From the Neoadjuvant I-SPY 2 TRIAL,” Cancer Research 83, no. 5_Supplement (2023): GS5-GS13.

[605] J. M. Pérez-García, A. Llombart-Cussac, and M. G. Cortés, “Pembrolizumab plus Eribulin in Hormone-receptor-positive, HER2-negative, Locally Recurrent or Metastatic Breast Cancer (KELLY): An Open-label, Multicentre, Single-arm, Phase II Trial,” European Journal of Cancer 148 (2021): 382-394.

[606] J. Cortes, D. W. Cescon, H. S. Rugo, et al., “Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-controlled, Double-blind, Phase 3 Clinical Trial,” Lancet 396, no. 10265 (2020): 1817-1828.

[607] P. Schmid, O. Lipatov, S. A. Im, et al., “Impact of pembrolizumab versus Chemotherapy on Health-related Quality of Life in Patients With Metastatic Triple-negative Breast Cancer: Results From the Phase 3 Randomised KEYNOTE-119 Study,” European Journal of Cancer 195 (2023): 113393.

[608] F. J. Ward, P. T. Kennedy, F. Al-Fatyan, L. N. Dahal, and R. Abu-Eid, “CTLA-4—two Pathways to Anti-tumour Immunity?,” Immunotherapy Advances 5, no. 1 (2024): 8.

[609] C. A. Santa-Maria, T. Kato, J. H. Park, et al., “A Pilot Study of Durvalumab and Tremelimumab and Immunogenomic Dynamics in Metastatic Breast Cancer,” Oncotarget 9, no. 27 (2018): 18985-18996.

[610] D. M. Jiang, A. Fyles, L. T. Nguyen, et al., “Phase I Study of Local Radiation and Tremelimumab in Patients With Inoperable Locally Recurrent or Metastatic Breast Cancer,” Oncotarget 10, no. 31 (2019): 2947-2958.

[611] S. Adams, M. Othus, S. P. Patel, et al., “A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609),” Clinical Cancer Research 28, no. 2 (2022): 271-278.

[612] S. Du, J. Yan, Y. Xue, Y. Zhong, and Y. Dong, “Adoptive Cell Therapy for Cancer Treatment,” Exploration 3, no. 4 (2023): 20210058.

[613] H. S. Han, R. L. Costa, H. H. Soliman, et al., “Phase I Study of Adoptive T Cell Therapy Following HER2-pulsed Dendritic Cell Vaccine and Pepinemab/trastuzumab in Patients With Metastatic HER2-positive Breast Cancer (MBC),” Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1113-TPS1113.

[614] R. Zhou, M. Yazdanifar, L. D. Roy, et al., “CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-negative Breast Cancer Growth,” Frontiers in immunology 10, no. MAY (2019): 441662.

[615] L. Xia, Z. Z. Zheng, J. Y. Liu, et al., “EGFR-targeted CAR-T Cells Are Potent and Specific in Suppressing Triple-negative Breast Cancer both in Vitro and in Vivo,” Clinical & Translational Immunology 9, no. 5 (2020): e1135.

[616] W. Xiao, W. Jiang, Z. Chen, et al., “Advance in Peptide-based Drug Development: Delivery Platforms, Therapeutics and Vaccines,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 1-56.

[617] E. A. Mittendorf, A. Ardavanis, J. K. Litton, et al., “Primary Analysis of a Prospective, Randomized, Single-blinded Phase II Trial Evaluating the HER2 Peptide GP2 Vaccine in Breast Cancer Patients to Prevent Recurrence,” Oncotarget 7, no. 40 (2016): 66192-66201.

[618] O. K. Burn, K. Farrand, T. Pritchard, et al., “Glycolipid-peptide Conjugate Vaccines Elicit CD8+ T-cell Responses and Prevent Breast Cancer Metastasis,” Clinical & Translational Immunology 11, no. 7 (2022): e1401.

[619] M. Tomasicchio, L. Semple, A. Esmail, et al., “An Autologous Dendritic Cell Vaccine Polarizes a Th-1 Response Which Is Tumoricidal to Patient-derived Breast Cancer Cells,” Cancer Immunology, Immunotherapy 68, no. 1 (2019): 71-83.

[620] H. Norell, I. Poschke, J. Charo, et al., “Vaccination With a Plasmid DNA Encoding HER-2/Neu Together With Low Doses of GM-CSF and IL-2 in Patients With Metastatic Breast Carcinoma: A Pilot Clinical Trial,” Journal of translational medicine 8 (2010): 53.

[621] V. Tiriveedhi, N. Tucker, J. Herndon, et al., “Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients With Stable Metastatic Breast Cancer,” Clinical Cancer Research 20, no. 23 (2014): 5964-5975.

[622] L. Liu, Y. Wang, L. Miao, et al., “Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer,” Molecular Therapy 26, no. 1 (2018): 45-55.

[623] W. Dai, X. Qiao, Y. Fang, et al., “Epigenetics-targeted Drugs: Current Paradigms and Future Challenges,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 1-71.

[624] S. Joshi, C. Garlapati, and R. Aneja, “Epigenetic Determinants of Racial Disparity in Breast Cancer: Looking Beyond Genetic Alterations,” Cancers 14, no. 8 (2022): 1903.

[625] L. Tao, Y. Zhou, Y. Luo, et al., “Epigenetic Regulation in Cancer Therapy: From Mechanisms to Clinical Advances,” MedComm - Oncology 3, no. 1 (2024): e59.

[626] Z. Kang, J. Wang, J. Liu, L. Du, and X. Liu, “Epigenetic Modifications in Breast Cancer: From Immune Escape Mechanisms to Therapeutic Target Discovery,” Frontiers in immunology 16 (2025): 1584087.

[627] R. Schröder, A. L. Illert, T. Erbes, C. Flotho, M. Lübbert, and J. Duque-Afonso, “The Epigenetics of Breast Cancer-Opportunities for Diagnostics, Risk Stratification and Therapy,” Epigenetics 17, no. 6 (2022): 612-624.

[628] R. M. Connolly, H. Li, R. C. Jankowitz, et al., “Combination Epigenetic Therapy in Advanced Breast Cancer With 5-azacitidine and Entinostat: A Phase II national cancer institute/Stand up to Cancer Study,” Clinical Cancer Research 23, no. 11 (2017): 2691-2701.

[629] J. Yu, B. Qin, A. M. Moyer, et al., “DNA Methyltransferase Expression in Triple-negative Breast Cancer Predicts Sensitivity to Decitabine,” Journal of Clinical Investigation 128, no. 6 (2018): 2376-2388.

[630] M. Asl, J. Asl, and M. Naghitorabi, “Comparison of the Effects of Olsalazine and Decitabine on the Expression of CDH1 and uPA Genes and Cytotoxicity in MDA-MB-231 Breast Cancer Cells,” Research in Pharmaceutical Sciences 16, no. 3 (2021): 278-285.

[631] A. Chequin, L. E. Costa, F. F. de Campos, et al., “Antitumoral Activity of Liraglutide, a New DNMT Inhibitor in Breast Cancer Cells in Vitro and in Vivo,” Chemico-Biological Interactions 349 (2021): 109641.

[632] M. Q. Shi, Y. Xu, X. Fu, et al., “Advances in Targeting Histone Deacetylase for Treatment of Solid Tumors,” Journal of hematology & oncology 17, no. 1 (2024): 1-20.

[633] Y. Zhang, H. Wang, Z. Zhan, L. Gan, and O. Bai, “Mechanisms of HDACs in Cancer Development,” Frontiers in immunology 16 (2025): 1529239.

[634] M. B. Palczewski, H. P. Kuschman, R. Bovee, J. R. Hickok, and D. D. Thomas, “Vorinostat Exhibits Anticancer Effects in Triple-negative Breast Cancer Cells by Preventing Nitric Oxide-driven Histone Deacetylation,” Biological Chemistry 402, no. 4 (2021): 501-512.

[635] S. Nimal, N. Kumbhar, Saruchi, et al., “Apigenin and Its Combination With Vorinostat Induces Apoptotic-mediated Cell Death in TNBC by Modulating the Epigenetic and Apoptotic Regulators and Related miRNAs,” Sci Reports 14, no. 1 (2024): 1-28.

[636] Z. Jiang, W. Li, X. Hu, et al., “Tucidinostat plus Exemestane for Postmenopausal Patients With Advanced, Hormone Receptor-positive Breast Cancer (ACE): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 20, no. 6 (2019): 806-815.

[637] J. Zhou, X. Wu, H. Zhang, et al., “Clinical Outcomes of Tucidinostat-based Therapy After Prior CDK4/6 Inhibitor Progression in Hormone Receptor-positive Heavily Pretreated Metastatic Breast Cancer,” The Breast 66 (2022): 255-261.

[638] H. Zhao, D. Li, Q. Li, et al., “Tucidinostat plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer,” The Oncologist 29, no. 6 (2024): e763-e770.

[639] T. Q. Gu, Y. L. Xiao, and Z. M. Shao, “Intratumor Heterogeneity in Breast Cancer: Tracing Its Origins and Translating Findings Into Clinical Practice,” Precision Medicine and Engineering 1, no. 1 (2024): 100006.

[640] P. C. Nowell, “The Clonal Evolution of Tumor Cell Populations,” Science (80-) 194, no. 4260 (1976): 23-28.

[641] I. Mavrommati, F. Johnson, G. V. Echeverria., and R. Natrajan, “Subclonal Heterogeneity and Evolution in Breast Cancer,” Npj Breast Cancer 7, no. 1 (2021): 1-9.

[642] C. K. Y. Ng, L. G. Martelotto, A. Gauthier, et al., “Intra-tumor Genetic Heterogeneity and Alternative Driver Genetic Alterations in Breast Cancers With Heterogeneous HER2 Gene Amplification,” Genome Biology 16, no. 1 (2015): 1-21.

[643] R. Wahdan-Alaswad, B. Liu, and A. D. Thor, “Targeted Lapatinib Anti-HER2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem,” Cancer Drug Resist 3, no. 2 (2020): 179.

[644] A. M. Tőkés, S. Vári-Kakas, J. Kulka, and B. Törőcsik, “Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas,” Frontiers in oncology 12 (2022): 850401.

[645] L. Silwal-Pandit, S. Nord, and H. Von Der Lippe Gythfeldt, “The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy With and Without Bevacizumab in Breast Cancer,” Clinical Cancer Research 23, no. 16 (2017): 4662-4670.

[646] C. Kim, R. Gao, E. Sei, et al., “Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing,” Cell 173, no. 4 (2018): 879-893. e13.

[647] A. Marra, S. Chandarlapaty, and S. Modi, “Management of Patients With Advanced-stage HER2-positive Breast Cancer: Current Evidence and Future Perspectives,” Nature reviews Clinical oncology 21, no. 3 (2024): 185-202.

[648] A. S. Silva, Y. Kam, Z. P. Khin, S. E. Minton, R. J. Gillies, and R. A. Gatenby, “Evolutionary Approaches to Prolong Progression-free Survival in Breast Cancer,” Cancer Research 72, no. 24 (2012): 6362-6370.

[649] D. Zardavas, A. Irrthum, C. Swanton, and M. Piccart, “Clinical Management of Breast Cancer Heterogeneity,” Nature reviews Clinical oncology 12, no. 7 (2015): 381-394.

[650] M. Li, T. Nishimura, Y. Takeuchi, et al., “FXYD3 functionally Demarcates an Ancestral Breast Cancer Stem Cell Subpopulation With Features of Drug-tolerant Persisters,” Journal of Clinical Investigation 133, no. 22 (2023): e166666.

[651] C. C. Liu, L. Chen, Y. W. Cai, et al., “Targeting EMSY-mediated Methionine Metabolism Is a Potential Therapeutic Strategy for Triple-negative Breast Cancer,” Cell Reports Medicine 5, no. 2 (2024): 101396.

[652] J. H. Kang and R. Zappasodi, “Modulating Treg Stability to Improve Cancer Immunotherapy,” Trends in Cancer 9, no. 11 (2023): 911-927.

[653] Y. Yang, S. Li, K. K. W. To, S. Zhu, F. Wang, and L. Fu, “Tumor-associated Macrophages Remodel the Suppressive Tumor Immune Microenvironment and Targeted Therapy for Immunotherapy,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 1-28.

[654] X. Lei, Y. N. Gou, J. Y. Hao, and X. J. Huang, “Mechanisms of TREM2 Mediated Immunosuppression and Regulation of Cancer Progression,” Frontiers in oncology 14 (2024): 1375729.

[655] I. Nasir, C. McGuinness, A. R. Poh, M. Ernst, P. K. Darcy, and K. L. Britt, “Tumor Macrophage Functional Heterogeneity Can Inform the Development of Novel Cancer Therapies,” Trends in Immunology 44, no. 12 (2023): 971-985.

[656] M. C. Papadimitriou, A. Pazaiti, K. Iliakopoulos, M. Markouli, V. Michalaki, and C. A. Papadimitriou, “Resistance to CDK4/6 Inhibition: Mechanisms and Strategies to Overcome a Therapeutic Problem in the Treatment of Hormone Receptor-positive Metastatic Breast Cancer,” Biochimica et Biophysica Acta: Molecular Cell Research 1869, no. 12 (2022): 119346.

[657] N. Sobhani, A. Fassl, G. Mondani, D. Generali, and T. Otto, “Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer,” Cells 10, no. 2 (2021): 293.

[658] N. Ashai and S. M. Swain, “Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets,” Cancers 15, no. 6 (2023): 1855.

[659] Q. Cheng, Z. Ma, Y. Shi, A. B. Parris, L. Kong, and X. Yang, “Fgfr1 overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-er Signaling to Promote Palbociclib Resistance in Luminal a Breast Cancer Cells,” Cells 10, no. 11 (2021): 3008.

[660] L. Formisano, Y. Lu, A. Servetto, et al., “Aberrant FGFR Signaling Mediates Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer,” Nature Communications 10, no. 1 (2019): 1-14.

[661] B. O'Leary, R. Cutts, and X. Huang, “Genomic Markers of Early Progression on Fulvestrant With or Without Palbociclib for ER+ Advanced Breast Cancer in the PALOMA-3 Trial,” Journal of Clinical Oncology 37, no. 15_suppl (2019): 1010-1010.

[662] J. Z. Drago, L. Formisano, D. Juric, et al., “FGFR1 amplification Mediates Endocrine Resistance but Retains Torc Sensitivity in Metastatic Hormone Receptor-positive (HR+) Breast Cancer,” Clinical Cancer Research 25, no. 21 (2019): 6443-6451.

[663] F. Giugliano, C. De Angelis, B. Pistilli, et al., “Overcoming Resistance to CDK4/6 Inhibitors in Hormone Receptor Positive, HER2 Negative Breast Cancer: Innovative Combinations and Emerging Strategies,” Cancer Treatment Reviews 139 (2025): 102980.

[664] S. Mouron, L. Manso, E. Caleiras, et al., “FGFR1 amplification or Overexpression and Hormonal Resistance in Luminal Breast Cancer: Rationale for a Triple Blockade of ER, CDK4/6, and FGFR1,” Breast Cancer Research 23, no. 1 (2021): 1-16.

[665] A. Musolino, M. Campone, P. Neven, et al., “Phase II, Randomized, Placebo-controlled Study of dovitinib in Combination With fulvestrant in Postmenopausal Patients With HR+, HER2- breast Cancer That Had Progressed During or After Prior Endocrine Therapy,” Breast Cancer Research 19, no. 1 (2017): 1-14.

[666] Y. K. Chae, F. Hong, C. Vaklavas, et al., “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W,” Journal of Clinical Oncology 38, no. 21 (2020): 2407-2417.

[667] I. A. Mayer, B. B. Haley, V. G. Abramson, et al., “Abstract PD1-03: A Phase Ib Trial of fulvestrant + CDK4/6 Inhibitor (CDK4/6i) palbociclib + Pan-FGFR Tyrosine Kinase Inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/ HER2-negative Metastatic Breast Cancer (MBC),” Cancer Research 81, no. 4_Supplement (2021): PD1-03.

[668] S. Pernas, C. Hernando, B. Bermejo, et al., “Abstract OT2-20-01: Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor-positive (HR+), FGFR1/2-positive Breast Cancer: Phase I Trial plus an Expansion Cohort,” Cancer Research 82, no. 4_Supplement (2022): OT2-20-01.

[669] N. Martínez-Jáñez, S. Pernas, J. Á. García-Sáenz, et al., “Abstract PO4-05-09: Phase I Study of the FGFR Inhibitor Rogaratinib, Fulvestrant and Palbociclib in Advanced Hormone Receptor-positive (HR+) Breast Cancer (BC) With FGFR1/2 Amplification and/or Overexpression (FGFR1/2+),” Cancer Research 84, no. 9_Supplement (2024): PO4-05-09.

[670] S. Malik and S. Zaheer, “The Impact of Liquid Biopsy in Breast Cancer: Redefining the Landscape of Non-invasive Precision Oncology,” The Journal of Liquid Biopsy 8 (2025): 100299.

[671] S. Pandey and P. Yadav, “Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications,” Practical Laboratory Medicine 43 (2025): e00446.

[672] S. M. Batool, A. Yekula, P. Khanna, et al., “The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring,” Cell Reports Medicine 4, no. 10 (2023): 101198.

[673] K. Venetis, F. Pepe, C. Pescia, et al., “ESR1 mutations in HR+/HER2-metastatic Breast Cancer: Enhancing the Accuracy of ctDNA Testing,” Cancer Treatment Reviews 121 (2023): 102642.

[674] D. Stergiopoulou, V. Georgoulias, A. Markou, and E. Lianidou, “Development and Validation of a Multi-marker Liquid Bead Array Assay for the Simultaneous Detection of PIK3CA and ESR1 Hotspot Mutations in Single Circulating Tumor Cells (CTCs),” Heliyon 10, no. 19 (2024): e37873.

[675] A. Christopoulou, M. Vlachou, S. Karageorgopoulou, et al., “Detection of ESR1 and PIK3CA Actionable Mutations in Breast Cancer Using Liquid Biopsy: A Step Toward Precision Medicine,” Journal of Clinical Oncology 43, no. 16_suppl (2025), https://doi.org/10.1200/JCO.2025.43.16_SUPPL.E13070.

[676] M. Sandbothe, B. Hasemeier, E. Schipper, et al., “Diagnostic Utility of ESR1 Mutation Detection in Liquid Biopsy of Metastatic Breast Cancer Patients,” Virchows Archiv (2024): 1-5, https://doi.org/10.1007/S00428-024-03942-1/FIGURES/3. Published online October 11.

[677] S. M. Hoy, “Elacestrant: First Approval,” Drugs 83, no. 6 (2023): 555-561.

[678] S. Borkar, F. Markus, A. Oetting, et al., “Detection of ESR1 Mutations in Tissue and Liquid Biopsy With Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights From Multi-Center Real Life Data of Almost 6000 Patients,” Cancers (Basel) 17, no. 8 (2025): 1266.

[679] F. C. Bidard, V. G. Kaklamani, P. Neven, et al., “Elacestrant (oral selective estrogen receptor degrader) versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial,” Journal of Clinical Oncology 32 (2022), https://doi.org/10.1200/JCO.22.00338/SUPPL_FILE/PROTOCOL_JCO.22.00338.PDF.

[680] F. C. Bidard, A. C. Hardy-Bessard, F. Dalenc, et al., “Switch to Fulvestrant and Palbociclib versus no Switch in Advanced Breast Cancer With Rising ESR1 Mutation During Aromatase Inhibitor and Palbociclib Therapy (PADA-1): A Randomised, Open-label, Multicentre, Phase 3 Trial,” The Lancet Oncology 23, no. 11 (2022): 1367-1377.

[681] M. Del Re, S. Crucitta, G. Lorenzini, et al., “PI3K Mutations Detected in Liquid Biopsy Are Associated to Reduced Sensitivity to CDK4/6 Inhibitors in Metastatic Breast Cancer Patients,” Pharmacological Research 163 (2021): 105241.

[682] M. Lawson, N. Cureton, and S. Ros, “The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance,” Cancer Research 83, no. 23 (2023): 3989-4004.

[683] A. Varkaris, F. Fece de la Cruz, and E. E. Martin, “Allosteric PI3Kα Inhibition Overcomes on-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations,” Cancer discovery 14, no. 2 (2024): 227-239.

[684] A. Tiwari, S. Mishra, and T. R. Kuo, “Current AI Technologies in Cancer Diagnostics and Treatment,” Molecular cancer 24, no. 1 (2025): 1-41.

[685] S. Sarvepalli and S. D. Vadarevu, “Role of Artificial Intelligence in Cancer Drug Discovery and Development,” Cancer Letters 627 (2025): 217821.

[686] F. G. Albani, S. S. Alghamdi, M. M. Almutairi, and T. Alqahtani, “Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design,” Drug Design, Development and Therapy 19 (2025): 5685-5707.

[687] A. Paliwal, M. A. Alam, P. Sharma, S. Jain, and S. Dhoundiyal, “Revolutionizing Cancer Research and Drug Discovery: The Role of Artificial Intelligence and Machine Learning,” Current Cancer Therapy Reviews 21, no. 3 (2024): 362-372.

[688] Y. Mao, D. Shangguan, Q. Huang, et al., “Emerging Artificial Intelligence-driven Precision Therapies in Tumor Drug Resistance: Recent Advances, Opportunities, and Challenges,” Molecular cancer 24, no. 1 (2025): 1-22.

[689] E. U. Alum, “AI-driven Biomarker Discovery: Enhancing Precision in Cancer Diagnosis and Prognosis,” Discover Oncology 16, no. 1 (2025): 1-12.

[690] M. Shirzad, M. Shaban, V. Mohammadzadeh, et al., “Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions,” BioNanoScience 15, no. 3 (2025): 1-33.

[691] K. Feng, Z. Yi, and B. Xu, “Artificial Intelligence and Breast Cancer Management: From Data to the Clinic,” Cancer Innovation 4, no. 2 (2025): e159.

[692] P. Uchikov, U. Khalid, G. H. Dedaj-Salad, et al., “Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care,” Life 14, no. 11 (2024): 1451.

[693] D. Singh, D. Sachdeva, and L. Singh, “Advancing Breast Cancer Drug Delivery: The Transformative Potential of Bioinformatics and Artificial Intelligence,” Current Cancer Therapy Reviews 21, no. 3 (2024): 254-264.

[694] K. Mayoral-Peña, O. I. González Peña, N. Artzi, and M. de Donato, “Biomarker Discovery for Early Breast Cancer Diagnosis Using Machine Learning on Transcriptomic Data for Biosensor Development,” Computers in Biology and Medicine 196, no. Pt A (2025): 110584.

[695] J. He, C. Zhang, A. Ozkan, et al., “Patient-derived Tumor Models and Their Distinctive Applications in Personalized Drug Therapy,” Mechanobiology in Medicine 1, no. 2 (2023): 100014.

[696] S. Mazzucchelli, L. Signati, L. Messa, et al., “Breast Cancer Patient-derived Organoids for the Investigation of Patient-specific Tumour Evolution,” Cancer cell international 24, no. 1 (2024): 1-18.

[697] H. Wu, W. Wang, Y. Zhang, et al., “Establishment of Patient-derived Organoids for Guiding Personalized Therapies in Breast Cancer Patients,” International Journal of Cancer 155, no. 2 (2024): 324-338.

[698] S. Qu, R. Xu, G. Yi, et al., “Patient-derived Organoids in human Cancer: A Platform for Fundamental Research and Precision Medicine,” Molecular Biomedicine 5, no. 1 (2024): 1-21.

[699] L. Tong, W. Cui, B. Zhang, et al., “Patient-derived Organoids in Precision Cancer Medicine,” Medicine 5, no. 11 (2024): 1351-1377.

[700] Y. Shi, Z. Guan, G. Cai, et al., “Patient-derived Organoids: A Promising Tool for Breast Cancer Research,” Frontiers in oncology 14 (2024): 1350935.

[701] P. Chen, X. Zhang, R. Ding, et al., “Patient-Derived Organoids Can Guide Personalized-Therapies for Patients With Advanced Breast Cancer,” Advancement of Science 8, no. 22 (2021): 2101176.

[702] N. Wajih, R. Erali, S. Forsythe, S. Soker, and K. Votanopoulos, “Abstract P3-09-02: Pateint Derived Breast Cancer Organoids as a Model for Testing Personalized Therapies,” Cancer Research 83, no. 5_Supplement (2023): P3-09-02.

[703] S. Saeki, K. Kumegawa, Y. Takahashi, et al., “Transcriptomic Intratumor Heterogeneity of Breast Cancer Patient-derived Organoids May Reflect the Unique Biological Features of the Tumor of Origin,” Breast Cancer Research 25, no. 1 (2023): 1-12.

[704] B. Policastro, N. Nissen, and C. L. Alves, “Deciphering Breast Tumor Heterogeneity through Patient-Derived Organoids and Circulating Tumor Cells,” Journal of Personalized Medicine 15, no. 7 (2025): 271.

[705] C. E. Önder, T. J. Ziegler, R. Becker, et al., “Advancing Cancer Therapy Predictions With Patient-Derived Organoid Models of Metastatic Breast Cancer,” Cancers (Basel) 15, no. 14 (2023): 3602.

[706] M. Kumari, K. Alam, A. Bhattacharya, et al., “Mechanically Induced Development and Maturation of 3D in-vitro Organoid Platform: An Organotypic Heterogeneous Microphysiological Model of Patient-derived Organoids With ER/PR/HER2+ Breast Cancer,” Frontiers in immunology 16 (2025): 1594405.

[707] S. Bhatia, M. Kramer, S. Russo, et al., “Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics,” Cancer Research 82, no. 7 (2022): 1174-1192.

[708] I. Psilopatis, A. Mantzari, K. Vrettou, and S. Theocharis, “The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening,” Biomed 11, no. 3 (2023): 773.

[709] W. Ying, H. Pi, X. He, and Y. Sheng, “Case Report: Personalized Treatment in Stage IV Breast Cancer Using the Patient-derived Organoids,” Frontiers in oncology 15 (2025): 1629690.

[710] Y. Liu, S. Liang, and J. Li, “Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids,” International Journal of Women's Health 17 (2025): 2395-2400.

[711] F. Liu, D. Ma, Q. Liu, and X. Qi, “A Novel Patient-derived Organoid Model for Triple-negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy for Screening Personalized Drugs,” Journal of Clinical Oncology 40, no. 16_suppl (2022): e12625-e12625.

[712] S. Ryu, H. S. Kim, S. Lee, et al., “Anti-cancer Drug Sensitivity Testing and Preclinical Evaluation of the Anti-cancer Potential of WEE1 Inhibitor in Triple-negative Breast Cancer Patient-derived Organoids and Xenograft Models,” Breast Cancer Research 27, no. 1 (2025): 1-20.

[713] R. Li, X. Hu, N. Ge, M. Kerin, and L. Barkley, “Abstract 3142: Patient-derived Models of Breast Cancer for Drug Screening and Precision Medicine Approaches,” Cancer Research 85, no. 8_Supplement_1 (2025): 3142-3142.

[714] T. Zhou and J. Zhang, “Types and Progress of Clinical Trial Design for Breast Cancer: A Narrative Review,” Translational Breast Cancer Research 4 (2023): 20.

[715] V. Subbiah, H. A. Burris, and R. Kurzrock, “Revolutionizing Cancer Drug Development: Harnessing the Potential of Basket Trials,” Cancer 130, no. 2 (2024): 186-200.

[716] V. Boni, B. Pistilli, I. Braña, et al., “Lurbinectedin, a Selective Inhibitor of Oncogenic Transcription, in Patients With Pretreated Germline BRCA1/2 Metastatic Breast Cancer: Results From a Phase II Basket Study,” ESMO Open 7, no. 5 (2022): 100571.

[717] Q. Ouyang, Y. Yin, L. Song, et al., “380MO SKB264 (MK-2870) in Previously Treated Hormone Receptor-positive (HR+)/HER2-negative Metastatic Breast Cancer (mBC): Results From a Phase I/II, Single-arm, Basket Trial,” Annals of Oncology 34 (2023): S337.

[718] A. F. C. Okines, G. Curigliano, N. Mizuno, et al., “Tucatinib and trastuzumab for Previously Treated HER2−Mutated Metastatic Breast Cancer (SGNTUC−019): A Phase 2 Basket Study,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 1105-1105.

[719] K. L. Jhaveri, S. A. Hurvitz, A. Brufsky, et al., “Efficacy and Genomic Analysis of HER2-mutant, Metastatic Triple-negative Breast Cancer Treated With neratinib Alone or in Combination With trastuzumab in the Phase 2 SUMMIT Basket Trial,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 1094-1094.

[720] D. C. Moore and A. S. Guinigundo, “Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine,” Journal of Advanced Practice Oncology 14, no. Suppl 1 (2023): 9.

[721] E. Fountzilas, A. M. Tsimberidou, H. Hiep Vo, and R. Kurzrock, “Tumor-agnostic Baskets to N-of-1 Platform Trials and Real-world Data: Transforming Precision Oncology Clinical Trial Design,” Cancer Treatment Reviews 125 (2024): 102703.

[722] H. Wang and D. Yee, “I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer,” Current Breast Cancer Reports 11, no. 4 (2019): 303-310.

[723] L. Pusztai, C. Yau, D. M. Wolf, et al., “Durvalumab With olaparib and paclitaxel for High-risk HER2-negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Trial,” Cancer Cell 39, no. 7 (2021): 989-998. e5.

[724] A. S. Clark, C. Yau, D. M. Wolf, et al., “Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial,” Nature Communications 12, no. 1 (2021): 1-11.

[725] D. W. Cescon, M. Rushton, N. LeVasseur, et al., “IND.241: A Canadian Cancer Trials Group Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- metastatic Breast,” Journal of Clinical Oncology 43, no. 16_suppl (2025), https://doi.org/10.1200/JCO.2025.43.16_SUPPL.TPS1121.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.